<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Mol Genet</journal-id><journal-id journal-id-type="iso-abbrev">Hum. Mol. Genet</journal-id><journal-id journal-id-type="publisher-id">hmg</journal-id><journal-title-group><journal-title>Human Molecular Genetics</journal-title></journal-title-group><issn pub-type="ppub">0964-6906</issn><issn pub-type="epub">1460-2083</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30007339</article-id><article-id pub-id-type="pmc">6216213</article-id><article-id pub-id-type="doi">10.1093/hmg/ddy252</article-id><article-id pub-id-type="publisher-id">ddy252</article-id><article-categories><subj-group subj-group-type="heading"><subject>General Article</subject></subj-group></article-categories><title-group><article-title>PIN1 is a new therapeutic target of craniosynostosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shin</surname><given-names>H R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bae</surname><given-names>H S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>B S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>H I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cho</surname><given-names>Y D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>W J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>K Y</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Y S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Woo</surname><given-names>K M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Baek</surname><given-names>J H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ryoo</surname><given-names>H M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref rid="cor1" ref-type="corresp"/><!--<email>hmryoo@snu.ac.kr</email>--></contrib></contrib-group><aff id="aff1"><label>1</label>BK21 Program, Department of Molecular Genetics and Dental Pharmacology and Therapeutics, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, Republic of Korea</aff><aff id="aff2"><label>2</label>Department of Periodontology, School of Dentistry, Seoul National University, Seoul, Republic of Korea</aff><aff id="aff3"><label>3</label>Department of Plastic and Reconstructive Surgery, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</aff><author-notes><corresp id="cor1">To whom correspondence should be addressed at: Department of Molecular Genetics and Dental Pharmacology, School of Dentistry, Seoul National University, Room 404, Building #86, 1 Kwanak-ro, Kwanak-gu, Seoul 088-26, Republic of Korea. Tel: +82 28802320; Fax: +82 27413103; Email: <email>hmryoo@snu.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>11</month><year>2018</year></pub-date><pub-date pub-type="epub" iso-8601-date="2018-07-11"><day>11</day><month>7</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>7</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>27</volume><issue>22</issue><fpage>3827</fpage><lpage>3839</lpage><history><date date-type="received"><day>16</day><month>1</month><year>2018</year></date><date date-type="rev-recd"><day>23</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>5</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2018. Published by Oxford University Press.</copyright-statement><copyright-year>2018</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ddy252.pdf"/><abstract><title>Abstract</title><p>Gain-of-function mutations in fibroblast growth factor receptors (FGFRs) cause congenital skeletal anomalies, including craniosynostosis (CS), which is characterized by the premature closure of craniofacial sutures. Apert syndrome (AS) is one of the severest forms of CS, and the only treatment is surgical expansion of prematurely fused sutures in infants. Previously, we demonstrated that the prolyl isomerase peptidyl-prolyl <italic>cis</italic>&#x02013;<italic>trans</italic> isomerase interacting 1 (PIN1) plays a critical role in mediating FGFR signaling and that <italic>Pin1<sup>+/&#x02212;</sup></italic> mice exhibit delayed closure of cranial sutures. In this study, using both genetic and pharmacological approaches, we tested whether PIN1 modulation could be used as a therapeutic regimen against AS. In the genetic approach, we crossbred <italic>Fgfr2<sup>S252W/+</sup></italic>, a mouse model of AS, and <italic>Pin1<sup>+/&#x02212;</sup></italic> mice. Downregulation of <italic>Pin1</italic> gene dosage attenuated premature cranial suture closure and other phenotypes of AS in <italic>Fgfr2<sup>S252W/+</sup></italic> mutant mice. In the pharmacological approach, we intraperitoneally administered juglone, a PIN1 enzyme inhibitor, to pregnant <italic>Fgfr2<sup>S252W/+</sup></italic> mutant mice and found that this treatment successfully interrupted fetal development of AS phenotypes. Primary cultured osteoblasts from <italic>Fgfr2<sup>S252W/+</sup></italic> mutant mice expressed high levels of FGFR2 downstream target genes, but this phenotype was attenuated by PIN1 inhibition. Post-translational stabilization and activation of Runt-related transcription factor 2 (RUNX2) in <italic>Fgfr2<sup>S252W/+</sup></italic> osteoblasts were also attenuated by PIN1 inhibition. Based on these observations, we conclude that PIN1 enzyme activity is important for FGFR2-induced RUNX2 activation and craniofacial suture morphogenesis. Moreover, these findings highlight that juglone or other PIN1 inhibitors represent viable alternatives to surgical intervention for treatment of CS and other hyperostotic diseases.</p></abstract><funding-group><award-group award-type="grant"><funding-source><named-content content-type="funder-name">National Research Foundation of Korea</named-content><named-content content-type="funder-identifier">10.13039/501100003725</named-content></funding-source><award-id>NRF-2014R1A2A2A01004865</award-id><award-id>NRF-2017R1A2B3011778</award-id></award-group></funding-group><counts><page-count count="13"/></counts></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Craniosynostosis (CS), defined as premature fusion of one or more cranial sutures, occurs in approximately 1 in 2500 live births (<xref rid="ref1" ref-type="bibr">1</xref>). Normally, the mammalian cranial vault consists of five major flat bones joined by structures known as cranial sutures (<xref rid="ref2" ref-type="bibr">2</xref>), which play a key role in cranial growth during development (<xref rid="ref3" ref-type="bibr">3</xref>). To permit brain growth in the early stage of life, the sutures should remain patent (<xref rid="ref1" ref-type="bibr">1</xref>). However, in CS, premature fusion prevents skull expansion to accommodate brain growth, potentially resulting in elevated intracranial pressure and multiple sequelae, including brain dysfunction, hydrocephalus, reduced intelligence and visual impairment due to pressure on the optic nerve (<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref4" ref-type="bibr">4</xref>). Currently, the only treatments for these disorders involve post-natal surgery.</p><p>In a prospective analysis of a cohort presenting with CS, the genes most frequently mutated were <italic>FGFR2</italic> (32%), <italic>FGFR3</italic> (25%), <italic>TWIST1</italic> (19%) and <italic>EFNB1</italic> (7%) (<xref rid="ref1" ref-type="bibr">1</xref>). Heterozygous mutations of <italic>FGFR2</italic> cause three classical CS syndromes: Apert, Crouzon and Pfeiffer (<xref rid="ref5" ref-type="bibr">5</xref>). Apert syndrome (AS), one of the severest forms of CS (<xref rid="ref6" ref-type="bibr">6</xref>,<xref rid="ref7" ref-type="bibr">7</xref>), is accompanied by facial abnormalities such as bicoronal synostosis, hypertelorism, mid-face hypoplasia, narrow arched palate and mitten-like syndactyly of fingers and toes (<xref rid="ref8" ref-type="bibr">8</xref>). Over 98% of cases are caused by specific missense mutations of <italic>FGFR2</italic>, either Ser252Trp (66%) or Pro253Arg (32%), in the linker between the immunoglobulin-like domain II (IgII) and IgIII domains (<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref9" ref-type="bibr">9</xref>). These substitutions increase the affinity and broaden the specificity of fibroblast growth factor (FGF)-ligand binding, explaining the cellular consequences of mutation, including accelerated proliferation and differentiation of osteoblasts in the cranial suture; premature differentiation is probably the most important factor leading to CS (<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref>). In this study, we focused on early coronal suture closure using a mouse model of AS that harbors a targeted mutation (S252W) in <italic>Fgfr2</italic>.</p><p>Peptidyl-prolyl <italic>cis</italic>&#x02013;<italic>trans</italic> isomerase NIMA-interacting 1 (PIN1) catalyzes post-phosphorylation conformational regulation. It binds only to specific pSer/Thr-Pro motifs, causing a <italic>cis</italic>&#x02013;<italic>trans</italic> conformational change of the substrate (<xref rid="ref11" ref-type="bibr">11</xref>). In a previous study, we demonstrated that <italic>RUNX2</italic> expression is regulated by the FGF/fibroblast growth factor receptor (FGFR) signaling pathway (<xref rid="ref12" ref-type="bibr">12</xref>) and that prolyl isomerization of Runt-related transcription factor 2 (RUNX2) mediated by PIN1 is crucial for acetylation and stabilization of RUNX2 in FGF/FGFR2 signaling (<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref14" ref-type="bibr">14</xref>). This molecular modification is essential for proper bone development (<xref rid="ref13" ref-type="bibr">13&#x02013;17</xref>). Excessive FGFR2 downstream signaling, including elevated RUNX2 activity and stability due to <italic>FGFR2</italic> mutations, could be a crucial driver of CS phenotypes.</p><p>Juglone (5-hydroxy-1,4-naphthoquinone) is a brown dye isolated from walnut shells and leaves of walnut trees (genus <italic>Juglans</italic>) (<xref rid="ref18" ref-type="bibr">18</xref>). Numerous <italic>in vitro</italic> and <italic>in vivo</italic> studies have shown that juglone effectively inhibits PIN1 activity (<xref rid="ref18" ref-type="bibr">18&#x02013;21</xref>). We hypothesized that suppression of PIN1 would normalize hyperactivated FGFR2 signaling, thereby rescuing the premature obliteration of coronal sutures that is the hallmark symptom of CS. To test our hypothesis, we pursued two independent approaches in <italic>Fgfr2<sup>S252W/+</sup></italic> mice, a model for human AS: a genetic approach targeting one allele of PIN1 and a pharmacological approach in which PIN1 activity was suppressed by administration of juglone during fetal development. Both approaches successfully attenuated CS phenotypes in the disease model mice, suggesting that PIN1 represents a promising molecular target for overcoming CS without surgery.</p></sec><sec id="sec2"><title>Results</title><sec id="sec3"><title>Inactivation of PIN1 prevents premature fusion of coronal suture in AS model mice</title><p>PIN1 is crucial for osteoblast differentiation mediated by FGF/FGFR2 signaling (<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref14" ref-type="bibr">14</xref>). To further investigate the relationship between PIN1 and skeletal abnormalities in our AS mouse model, we reduced the dose of PIN1 by crossing <italic>Pin1<sup>+/&#x02212;</sup>Fgfr2<sup>Neo-S252W/+</sup></italic> with <italic>Pin1<sup>+/&#x02212;</sup>EIIA-Cre<sup>+/&#x02212;</sup></italic> (<italic>Pin1<sup>+/&#x02212;</sup>;Fgfr2<sup>S252W/+</sup></italic>) to generate compound mutant mice. These genetic manipulations resulted in significantly different overall phenotypes (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S1</xref>). Micro-computed tomography (CT) scans, performed to observe mineralized tissues, revealed that newborn <italic>Fgfr2<sup>S252W/+</sup></italic> mice had abnormalities, including a dome-shaped skull and a shortened skull length (<xref rid="f1" ref-type="fig">Fig. 1A</xref> and <xref rid="f1" ref-type="fig">B</xref>), compared with wild-type (WT) mice, as described previously (<xref rid="ref22" ref-type="bibr">22</xref>). In the case of a normal suture in WT newborn mice, the suture is not completely fused and mineralized. So it appears as empty on micro-CT scan images of the skull as previously described (<xref rid="ref23" ref-type="bibr">23&#x02013;27</xref>). However, the CSs of coronal sutures of <italic>Fgfr2<sup>S252W/+</sup></italic> mice were completely fused, which were rescued in <italic>Pin1<sup>+/&#x02212;</sup>;Fgfr2<sup>S252W/+</sup></italic> mice (<xref rid="f1" ref-type="fig">Fig. 1A</xref> and <xref rid="f1" ref-type="fig">B</xref>, yellow arrows). As a reference, a schematic diagram (<xref rid="ref24" ref-type="bibr">24</xref>) is shown in <xref rid="f1" ref-type="fig">Figure 1C</xref> and <xref rid="f1" ref-type="fig">D</xref>. <italic>Pin1<sup>+/&#x02212;</sup>;Fgfr2<sup>S252W/+</sup></italic> mice had longer skull (<xref rid="f1" ref-type="fig">Fig. 1E</xref>) and nasal region (<xref rid="f1" ref-type="fig">Fig. 1F</xref>) and smaller skull height (<xref rid="f1" ref-type="fig">Fig. 1G</xref>) and intercanthal distance than <italic>Fgfr2<sup>S252W/+</sup></italic> mice (<xref rid="f1" ref-type="fig">Fig. 1H</xref>). To observe histological changes, we prepared sagittal sections of the skull. As reported previously, <italic>Fgfr2<sup>S252W/+</sup></italic> coronal sutures were completely fused (<xref rid="f1" ref-type="fig">Fig. 1I</xref>). In contrast, <italic>Pin1<sup>+/&#x02212;</sup>;Fgfr2<sup>S252W/+</sup></italic> coronal sutures remained in the differentiated state and were not yet completely fused (<xref rid="f1" ref-type="fig">Fig. 1I</xref>). The incidence of coronal and frontal&#x02013;nasal suture fusion depended on the genotype (<xref rid="TB1" ref-type="table">Table 1</xref>). Reduced body length in <italic>Fgfr2<sup>S252W/+</sup></italic> mice was also restored by genetic deletion of one allele of <italic>Pin1</italic>; this effect was statistically significant (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S1</xref>). These observations suggest that inactivation of PIN1 prevents CS of coronal sutures in <italic>Fgfr2<sup>S252W/+</sup></italic> mice.</p><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Rescue of premature fusion of coronal suture in <italic>Fgfr2<sup>S252W/+</sup></italic> mice by removal of one allele of <italic>Pin1</italic>. (<bold>A</bold>, <bold>B</bold>) Representative micro-CTs of skulls from WT, <italic>Pin1<sup>+/&#x02212;</sup></italic>, <italic>Fgfr2<sup>S252W/+</sup></italic> and <italic>Pin1<sup>+/&#x02212;</sup>;Fgfr2<sup>S252W/+</sup></italic> mice (<italic>n</italic>&#x000a0;=&#x000a0;5). Superior views (<bold>A</bold>) and lateral views (<bold>B</bold>) of skull calvaria. Removal of one allele of <italic>Pin1</italic> rescued premature fusion of coronal suture (yellow arrows), a CS calvarial phenotype, and the frontal&#x02013;nasal suture (blue arrows). (<bold>C</bold>, <bold>D</bold>) Schematic diagram and landmarks of mouse skull vault. The mouse skull consists of paired frontal bones (fr), paired parietal bones (pa) and the interparietal bone (ipa), intervened by the coronal, sagittal, metopic and lambdoid sutures. The 3D coordinates of specific craniofacial landmarks, shown in (<bold>C</bold>) and (<bold>D</bold>), were used for morphometric analyses of the skulls. Green lines represent linear distances corresponding to the length of the nasal region (lnsla&#x02013;lflac) and the skull length (rnsla&#x02013;rocc). Red line indicates skull height (lpto&#x02013;bas). Orange lines indicating intercanthal distance (lflac&#x02013;rflac) show linear distances corresponding to facial width. (<bold>E</bold>&#x02013;<bold>H</bold>) Representative micro-CT results of skulls, shown as bar graphs (<italic>n</italic>&#x000a0;=&#x000a0;5 in each group; <sup>*</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; <sup>**</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.005; <sup>***</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). (<bold>I</bold>) Histological sections of coronal sutures in newborn mice. Arrows indicate growing fronts of frontal and parietal bones. The calvarial bone is highlighted with dotted lines.</p></caption><graphic xlink:href="ddy252f1"/></fig><table-wrap id="TB1" orientation="portrait" position="float"><label>Table 1</label><caption><p>The incidence of coronal and frontal&#x02013;nasal suture fusion according to genotype</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Genotype</th><th align="left" rowspan="1" colspan="1">Coronal suture fusion (between frontal and parietal bone)</th><th align="left" rowspan="1" colspan="1">Ratio (%)</th><th align="left" rowspan="1" colspan="1">Frontal&#x02013;nasal suture fusion (between nasal and frontal bone)</th><th align="left" rowspan="1" colspan="1">Ratio (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WT (<italic>n</italic>&#x000a0;=&#x000a0;5)</td><td align="left" rowspan="1" colspan="1">0/5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0/5</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Pin1<sup>+/&#x02212;</sup></italic> (<italic>n</italic>&#x000a0;=&#x000a0;5)</td><td align="left" rowspan="1" colspan="1">0/5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0/5</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Fgfr2<sup>S252W/+</sup></italic> (<italic>n</italic>&#x000a0;=&#x000a0;5)</td><td align="left" rowspan="1" colspan="1">5/5</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">5/5</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Pin1<sup>+/&#x02212;</sup>Fgfr2<sup>S252W/+</sup></italic> (<italic>n</italic>&#x000a0;=&#x000a0;5)</td><td align="left" rowspan="1" colspan="1">0/5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2/5</td><td align="left" rowspan="1" colspan="1">40</td></tr></tbody></table></table-wrap></sec><sec id="sec4"><title>Restoration of craniofacial skeletal abnormalities in juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic> mice</title><p>To assess the relevance of these findings to patients, we treated our model mice with juglone, a pharmacological inhibitor of PIN1 (<xref rid="ref18" ref-type="bibr">18</xref>). Prior to these experiments, we optimized the dose of juglone based on toxicity tests (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S2</xref>). For this purpose, pregnant mice were injected once daily with juglone (0, 0.01, 0.1, 1 or 2.5&#x000a0;mg/kg) from E14.5 to E18.5; dynamic skeletogenesis of the calvaria occurs around E12.5 (<xref rid="ref28" ref-type="bibr">28</xref>). Newborn mice were sacrificed and examined to determine the highest concentration that did not decrease the number of littermates (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S2A</xref>) but significantly affected the skeletal phenotype (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S2B</xref>); based on the results of this analysis, we set the concentration of juglone to 1&#x000a0;mg/kg. When pregnant mice were given daily injection of 1&#x000a0;mg/kg juglone, littermates which comprised WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mice were birthed as an equal proportion in control and juglone-injected groups (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S2C</xref>).</p><p>The level of skull development was evaluated by embryonic skeletal staining and histological analysis (<xref rid="f2" ref-type="fig">Fig. 2A</xref>&#x02013;<xref rid="f2" ref-type="fig">C</xref>). As in the experiments described earlier, <italic>Fgfr2<sup>S252W/+</sup></italic> mice exhibited multiple abnormalities, including a dome-shaped skull (<xref rid="f2" ref-type="fig">Fig. 2A</xref>), a shortened skull length (<xref rid="f2" ref-type="fig">Fig. 2A</xref> and <xref rid="f2" ref-type="fig">B</xref>), widely spaced eyes (<xref rid="f2" ref-type="fig">Fig. 2B</xref>, yellow line), premature closure of the coronal suture (<xref rid="f2" ref-type="fig">Fig. 2A</xref>, white arrowhead; <xref rid="f2" ref-type="fig">Fig. 2B</xref>, arrow) and nasal suture (<xref rid="f2" ref-type="fig">Fig. 2A</xref>, black arrowhead), whereas juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic> mice showed recovery from premature coronal suture fusion (5/5, 100%) and frontal&#x02013;nasal suture fusion (2/5, 40%) (<xref rid="TB2" ref-type="table">Table 2</xref>). Next, we made histological observations of the coronal sections in sagittal sections of calvaria (<xref rid="f2" ref-type="fig">Fig. 2C</xref>). <italic>Fgfr2<sup>S252W/+</sup></italic> mice exhibited premature closure of coronal sutures, whereas closure occurred normally in juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic> mice despite expression of the mutant <italic>Fgfr2<sup>S252W</sup></italic> allele (<xref rid="f2" ref-type="fig">Fig. 2C</xref>). To quantify restoration of CS calvaria phenotypes by juglone treatment, we obtained micro-CT scans of skulls from each group and littermate controls at birth (<xref rid="f2" ref-type="fig">Fig. 2D</xref> and <xref rid="f2" ref-type="fig">E</xref>). Images from the top (<xref rid="f2" ref-type="fig">Fig. 2D</xref>) and the side (<xref rid="f2" ref-type="fig">Fig. 2E</xref>) of <italic>Fgfr2<sup>S252W/+</sup></italic> mice calvaria showed that coronal (yellow arrow) and nasal (blue arrow) sutures were completely overlapping and calcified. In contrast, juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic> mice had calvarial phenotypes similar to those of WT mice. The incidence of coronal and frontal&#x02013;nasal suture fusion depended on the experimental group (<xref rid="TB2" ref-type="table">Table 2</xref>). We then looked for morphological differences in specific craniofacial features between groups, in comparison with WT littermate mice (<xref rid="f2" ref-type="fig">Fig. 2D</xref> and <xref rid="f2" ref-type="fig">E</xref>), using <xref rid="f1" ref-type="fig">Figure 1C</xref> and <xref rid="f1" ref-type="fig">D</xref> and reference landmarks (<xref rid="ref24" ref-type="bibr">24</xref>,<xref rid="ref29" ref-type="bibr">29</xref>). The lengths of the skull and nasal region were significantly shorter in <italic>Fgfr2<sup>S252W/+</sup></italic> mice than in WT mice (<xref rid="f2" ref-type="fig">Fig. 2F</xref> and <xref rid="f2" ref-type="fig">G</xref>). In addition, cranial height and interocular distance were larger in <italic>Fgfr2<sup>S252W/+</sup></italic> mice than in WT mice, likely due to brain development under size limitations (<xref rid="f2" ref-type="fig">Fig. 2H</xref> and <xref rid="f2" ref-type="fig">I</xref>); this difference was statistically significant. The reduced body length of <italic>Fgfr2<sup>S252W/+</sup></italic> mice was rescued by juglone treatment (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S3</xref>), and the overall phenotypes of juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic> mice were similar to those of WT mice. Together, these results indicate that juglone attenuates abnormal calvaria bone formation in <italic>Fgfr2<sup>S252W/+</sup></italic> mice.</p><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Craniosynostosis phenotypes in AS model mice are rescued by treatment with the PIN1 inhibitor juglone. Pregnant mice were intraperitoneally injected with 1&#x000a0;mg/kg juglone (<italic>Fgfr2<sup>S252W/+</sup></italic> + juglone) or vehicle (<italic>Fgfr2<sup>S252W/+</sup></italic>) once a day from E14.5 to E18.5. WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mice were sacrificed at birth. (<bold>A</bold>, <bold>B</bold>) Mouse calvaria were examined after Alizarin Red S and Alcian Blue staining. Black arrowheads, frontal&#x02013;nasal suture; white arrowheads, coronal suture (<bold>A</bold>). Both sutures were already closed in <italic>Fgfr2<sup>S252W/+</sup></italic> mice, whereas those of WT and <italic>Fgfr2<sup>S252W/+</sup></italic> + juglone mice remained open. Coronal views of the heads of the same animals are shown in (<bold>B</bold>). Intercanthal distance (yellow lines) was significantly wider in <italic>Fgfr2<sup>S252W/+</sup></italic> mice than in control mice. Arrows indicate a coronal suture that is almost overlapping in <italic>Fgfr2<sup>S252W/+</sup></italic>, whereas sutures in the other group remain open. (<bold>C</bold>) Histological sections of coronal sutures in newborn mice. Arrows indicate growing fronts of frontal and parietal bones. Note that suture overlap is much more pronounced in <italic>Fgfr2<sup>S252W/+</sup></italic> mice than in the other groups. The calvarial bone is highlighted with dotted lines. (<bold>D</bold>, <bold>E</bold>) Representative micro-CTs of skulls from WT, <italic>Fgfr2<sup>S252W/+</sup></italic> and juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic> mice (<italic>n</italic>&#x000a0;=&#x000a0;5). Superior views (<bold>D</bold>) and lateral views (<bold>F</bold>) of skull calvaria. Yellow arrows indicate rescue of early fusion of coronal suture (5/5, 100%), and blue arrows indicate rescue of the distorted frontal&#x02013;nasal suture (2/5, 40%) of mutant mice by juglone. Green lines represent linear distances corresponding to the lengths of the nasal region and the skull. The red line indicates skull height, whereas the yellow lines, such as the neurocranial width at intercanthal distance (lflac&#x02013;rflac), indicate linear distances corresponding to facial width. (<bold>F</bold>&#x02013;<bold>I</bold>) Representative micro-CT results of skulls are shown in bar graphs (<italic>n</italic>&#x000a0;=&#x000a0;5 in each group; <sup>*</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; <sup>**</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.005; <sup>***</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Statistically significant differences indicate rescue of the CS calvarial phenotype.</p></caption><graphic xlink:href="ddy252f2"/></fig><table-wrap id="TB2" orientation="portrait" position="float"><label>Table 2</label><caption><p>The incidence of suture fusion according to experimental group</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Genotype</th><th align="left" rowspan="1" colspan="1">Coronal suture fusion (between frontal and parietal bone)</th><th align="left" rowspan="1" colspan="1">Ratio (%)</th><th align="left" rowspan="1" colspan="1">Frontal&#x02013;nasal suture fusion (between nasal and frontal bone)</th><th align="left" rowspan="1" colspan="1">Ratio (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">WT (<italic>n</italic>&#x000a0;=&#x000a0;5)</td><td align="left" rowspan="1" colspan="1">0/5</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">0/5</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Fgfr2<sup>S252W/+</sup></italic> (<italic>n</italic>&#x000a0;=&#x000a0;5)</td><td align="left" rowspan="1" colspan="1">5/5</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">5/5</td><td align="left" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Fgfr2<sup>S252W/+</sup></italic> + juglone (<italic>n</italic>&#x000a0;=&#x000a0;5)</td><td align="left" rowspan="1" colspan="1">1/5</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">3/5</td><td align="left" rowspan="1" colspan="1">60</td></tr></tbody></table></table-wrap></sec><sec id="sec5"><title>Juglone affects expression of genes downstream of FGF/FGFR2</title><p>Previously, we found links between FGF/FGFR2 signaling and PIN1 in cell culture (<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref30" ref-type="bibr">30</xref>). Therefore, we examined whether rescue by juglone, which has an inhibitory concentration 50 (IC50) value of 13.55&#x000a0;&#x003bc;<sc>m</sc> in primary osteoblasts (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S4</xref>), affected expression modulators and downstream genes of FGFR signaling, including <italic>Dusp6</italic> and two genes in the Sprouty family, <italic>Spry2</italic> and <italic>Spry3</italic> (<xref rid="ref22" ref-type="bibr">22</xref>). Extracellular signal-regulated kinase 1/2 (ERK1/2) activation triggers the transcription of <italic>Dusp6</italic> mRNA, and the Dusp6 protein inactivates ERK1/2, resulting in a negative feedback loop activated by FGF during somite development (<xref rid="ref31" ref-type="bibr">31</xref>). Similarly, members of the Sprouty family antagonize FGF and FGFR signaling (<xref rid="ref32" ref-type="bibr">32</xref>). To assess the effect of juglone on FGF/FGFR2 signaling, we measured mRNA expression of <italic>Dusp6</italic>, <italic>Spry2</italic> and <italic>Spry3</italic> by reverse transcription polymerase chain reaction (RT-PCR). Expression of all three genes was elevated in primary mouse calvarial cells from <italic>Fgfr2<sup>S252W/+</sup></italic> mice (<xref rid="f3" ref-type="fig">Fig. 3A</xref>&#x02013;<xref rid="f3" ref-type="fig">C</xref>) and MC3T3-E1 cells overexpressing <italic>Fgfr2</italic><sup>S252W</sup> from a plasmid (<xref rid="f3" ref-type="fig">Fig. 3D</xref>&#x02013;<xref rid="f3" ref-type="fig">F</xref>), in which FGF/FGFR2 signaling was hyperactivated in comparison with WT primary mouse calvarial cells and <italic>Fgfr2</italic><sup>WT</sup>-overexpressing MC3T3-E1 cells. After juglone treatment, expression of these genes decreased in a dose-dependent manner (<xref rid="f3" ref-type="fig">Fig. 3A</xref>&#x02013;<xref rid="f3" ref-type="fig">E</xref>). We measured the expression of <italic>18s rRNA</italic> as a negative control. As expected, expression of <italic>18s rRNA</italic> gene was not affected by mutation of <italic>Fgfr2</italic> in primary mouse calvarial cells (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S5A</xref>). We also confirmed that the increased expression of target genes in <italic>Fgfr2<sup>S252W/+</sup></italic> primary mouse calvarial cells was suppressed by U0126 treatment, as reported previously (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S5B</xref>&#x02013;<xref ref-type="supplementary-material" rid="sup1">D</xref>) (<xref rid="ref22" ref-type="bibr">22</xref>). These observations indicate that juglone inhibits the downstream genes of FGF/FGFR2 signaling.</p><fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Expression of target genes changes upon treatment with juglone. <bold>(A</bold>, <bold>B</bold>) Relative expression levels of FGFR2 signaling modulators and downstream genes, based on qPCR analysis of WT and <italic>Fgfr2<sup>S252W/+</sup></italic> calvaria cells (<italic>n</italic>&#x000a0;=&#x000a0;3) following treatment with different dosages of juglone for 1&#x000a0;day. (<bold>C</bold>&#x02013;<bold>E</bold>) 70% confluent MC3T3-E1 cells were transfected with <italic>Fgfr2</italic><sup>WT</sup> or <italic>Fgfr2<sup>S252W</sup></italic> mutant expression plasmids. After 24&#x000a0;h, cells were treated with 0, 1 and 10&#x000a0;&#x003bc;<sc>m</sc> of juglone for 1&#x000a0;day. mRNA levels of FGFR signaling modulators and downstream genes, such as <italic>Dusp6</italic> (<bold>C</bold>) and the <italic>Sprouty</italic> family genes (<italic>Spry2</italic>, <italic>3</italic>) (<bold>D, E</bold>), were analyzed quantitatively (<italic>n</italic>&#x000a0;=&#x000a0;3 in each group; <sup>*</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; <sup>**</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.005; <sup>***</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). The level of each mRNA was normalized to that of <italic>Gapdh</italic> in the same sample.</p></caption><graphic xlink:href="ddy252f3"/></fig></sec><sec id="sec6"><title>Juglone restores RUNX2 hyperstability in <italic>Fgfr2<sup>S252W/+</sup></italic> mouse calvarial cells by decreasing acetylation of RUNX2</title><p>RUNX2, a key transcription factor in osteoblast differentiation, triggers mesenchymal stem cells to differentiate into osteoblasts (<xref rid="ref33" ref-type="bibr">33</xref>). The importance of RUNX2 in mammalian skeletal development has been clearly demonstrated by the observation that <italic>RUNX2</italic> knockout mice lack both mature osteoblasts and a mineralized skeleton, including the calvaria (<xref rid="ref34" ref-type="bibr">34</xref>). In addition, <italic>RUNX2</italic> expression is localized to the critical area of cranial suture closure (<xref rid="ref35" ref-type="bibr">35</xref>). To determine the mechanism underlying restoration of the calvarial phenotype of <italic>Fgfr2<sup>S252W/+</sup></italic> mice by juglone, we assessed endogenous RUNX2 expression in WT and <italic>Fgfr2<sup>S252W/+</sup></italic> primary mouse calvarial cells by immunofluorescence analysis (<xref rid="f4" ref-type="fig">Fig. 4A</xref>). In WT cells, we observed weak staining for endogenous RUNX2 in the nucleus (<xref rid="f4" ref-type="fig">Fig. 4A</xref>, first row). After treatment of WT cells with juglone, the level of endogenous RUNX2 was slightly reduced (<xref rid="f4" ref-type="fig">Fig. 4A</xref>, second row). <italic>Fgfr2<sup>S252W/+</sup></italic> cells had more endogenous RUNX2 in the nucleus than WT cells (<xref rid="f4" ref-type="fig">Fig. 4A</xref>, third row), but juglone treatment significantly reduced the level of RUNX2 in these <italic>Fgfr2<sup>S252W/+</sup></italic> primary mouse calvarial cells (<xref rid="f4" ref-type="fig">Fig. 4A</xref>, fourth row), which was quantified by measuring the intensity of the nuclear staining (green) area (<xref rid="f4" ref-type="fig">Fig. 4B</xref>).</p><fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>RUNX2 is overactivated in <italic>Fgfr2<sup>S252W/+</sup></italic> mice, and juglone destabilizes RUNX2 by decreasing acetylation. (<bold>A</bold>) Endogenous RUNX2 was detected by immunofluorescence and immunocytochemistry. Primary mouse calvarial cells from WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mice were treated with 5&#x000a0;&#x003bc;<sc>m</sc> juglone for 24&#x000a0;h. Cells were fixed, and endogenous proteins were immunostained with anti-RUNX2 (green) and anti-RNA POL II (red) antibodies, as well as 4&#x02032;,6-diamidino-2-phenylindole (blue). In the merged image, RUNX2 and RNA POL II colocalization (yellow) was observed as foci, particularly in <italic>Fgfr2<sup>S252W</sup></italic> mutant-expressing cells. (<bold>B</bold>) Endogenous intranuclear RUNX2 was quantified, and results are shown as a sigma plot (<italic>n</italic>&#x000a0;=&#x000a0;20 in each group; <sup>*</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; <sup>**</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.005; <sup>***</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). (<bold>C</bold>) The numbers of RUNX2/RNA POL II-colocalized foci were quantified (<italic>n</italic>&#x000a0;=&#x000a0;10 in each group; <sup>*</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; <sup>**</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.005; <sup>***</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001). (<bold>D</bold>) Abundance of endogenous RUNX2 in dissociated nuclear extracts, as determined by immunoblot assay. (<bold>E</bold>) Degree of acetylation of RUNX2, as determined by IP with anti-acetyl-lysine antibody from dissociated nuclear extracts. (<bold>F</bold>, <bold>G</bold>) RUNX2 stability analysis. <italic>Myc-tagged Runx2</italic> plasmid was transfected into primary mouse calvaria cells. After 24&#x000a0;h, cells were pre-treated with or without 5&#x000a0;&#x003bc;<sc>m</sc> juglone for 1&#x000a0;h and then treated with 10&#x000a0;&#x003bc;g/ml CHX for the indicated times. Cells were harvested and followed by immunoblotting with the indicated antibodies. &#x003b2;-Actin was used as a loading control. (<bold>G</bold>) Band intensities of RUNX2 in F were quantitated and plotted against time. (<bold>H</bold>) RUNX2 in calvaria tissue from coronal sutures of newborn mice was detected by IHC using Alcian Blue counterstaining.</p></caption><graphic xlink:href="ddy252f4"/></fig><p>Increased nuclear localization of RUNX2 in <italic>Fgfr2<sup>S252W/+</sup></italic> cells was not enough to conclude that its activity as a transcription factor in these cells was increased. Many previous papers have reported that active transcription factors appear in the nucleus as foci with RNA polymerase (POL) II (<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref36" ref-type="bibr">36&#x02013;39</xref>). Thus, to determine whether its increased localization to the nucleus coincides with an increase in its activity, we quantified the number of RUNX2/RNA POL II-colocalized foci. Indeed, the number of these foci was higher in <italic>Fgfr2<sup>S252W/+</sup></italic> cells than in WT cells and decreased after juglone treatment (<xref rid="f4" ref-type="fig">Fig. 4C</xref>).</p><p>We conducted nuclear fractionation and western blot analysis; we found that the increased levels of nuclear endogenous RUNX2 compared with that in WT cells were reduced by juglone treatment (<xref rid="f4" ref-type="fig">Fig. 4D</xref>). We showed previously that post-translational modification (PTM) is important for RUNX2 stabilization (<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref30" ref-type="bibr">30</xref>). In particular, PIN1-mediated structural modification of RUNX2 is an indispensable step connecting phosphorylation, acetylation and transcriptional activation of RUNX2 by FGF signaling (<xref rid="ref14" ref-type="bibr">14</xref>). To determine the mechanism by which juglone restored nuclear RUNX2 to WT level, we examined the acetylation of RUNX2. Immunoprecipitation (IP) assays revealed that acetylation of RUNX2 was higher in <italic>Fgfr2</italic><sup><italic>S252W/</italic>+</sup> mouse calvarial cells than in WT cells (<xref rid="f4" ref-type="fig">Fig. 4E</xref>). In contrast, the acetylated RUNX2 level returned to normal in juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic> mouse calvarial cells (<xref rid="f4" ref-type="fig">Fig. 4E</xref>). Next, we investigated whether juglone affects the stability of the RUNX2. FGF signaling promotes <italic>Runx2</italic> expression in osteoblasts (<xref rid="ref12" ref-type="bibr">12</xref>); however, we wanted to test the effects of juglone on PTM of RUNX2, as this affects the stability of RUNX2. To this end, we transfected <italic>Myc</italic>-tagged <italic>Runx2</italic> plasmid into WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mouse calvarial cells and monitored the stability of exogenous RUNX2 (<xref rid="f4" ref-type="fig">Fig. 4F</xref>). In WT mouse calvarial cells, treatment with cycloheximide (CHX), an inhibitor of protein synthesis, almost decreased the level of exogenous RUNX2 within 3&#x000a0;h, whereas in <italic>Fgfr2<sup>S252W/+</sup></italic> cells, its level remained stable in for over 9&#x000a0;h (<xref rid="f4" ref-type="fig">Fig. 4F</xref>). However, when <italic>Fgfr2<sup>S252W/+</sup></italic> mouse calvarial cells were treated with juglone and CHX, the level of RUNX2 was reduced appreciably (<xref rid="f4" ref-type="fig">Fig. 4F</xref>). We quantified the changes in RUNX2 expression over time (<xref rid="f4" ref-type="fig">Fig. 4G</xref>). These results strongly indicate that isomerization of RUNX2 by PIN1, which is critical for RUNX2 stabilization through acetylation, is inhibited by juglone, thereby reversing the effects of the <italic>Fgfr2</italic><sup>S252W</sup> mutation and the associated stabilization of RUNX2. Using immunohistochemistry (IHC), we confirmed that elevated RUNX2 levels in <italic>Fgfr2<sup>S252W/+</sup></italic> mouse coronal sutures were attenuated by juglone treatment (<xref rid="f4" ref-type="fig">Fig. 4H</xref>). Cell morphology was also different because cuboidal cells, such as WT and juglone-treated <italic>Fgfr2<sup>S252W/+</sup></italic><sub>,</sub> were undergoing differentiation (<xref rid="ref40" ref-type="bibr">40</xref>). However, the bone lining cells in <italic>Fgfr2<sup>S252W/+</sup></italic> are already differentiated (<xref rid="ref40" ref-type="bibr">40</xref>); RUNX2-stained cells had a different histological appearance. Together, these results suggest that the <italic>Fgfr2</italic> mutation in osteoblasts increase the amount of RUNX2 and juglone restored RUNX2 to near its normal WT level.</p></sec><sec id="sec7"><title>Juglone attenuates <italic>Fgfr2</italic> mutation-induced osteoblast proliferation and differentiation in CS</title><p>As shown in <xref rid="f4" ref-type="fig">Figure 4</xref>, juglone prevented excessive RUNX2 acetylation and stabilization. Because acetylated and stabilized RUNX2 has transactivation activity and regulates cell proliferation and differentiation (<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref42" ref-type="bibr">42</xref>), we examined the <italic>in vitro</italic> effects of juglone on osteoblast differentiation. RUNX2 activity was assessed in a reporter assay using 6XOSE2, a construct that contains six tandem repeats of osteoblast-specific <italic>cis</italic>-element 2 (<xref rid="ref12" ref-type="bibr">12</xref>). Primary mouse calvarial cells of <italic>Fgfr2<sup>S252W/+</sup></italic> mice exhibited approximately 2.5-fold higher levels of RUNX2 activity than those of WT mice (<xref rid="f5" ref-type="fig">Fig. 5A</xref>). However, the elevated RUNX2 activity caused by <italic>Fgfr2<sup>S252W</sup></italic> mutation decreased in a dose-dependent manner following juglone treatment (<xref rid="f5" ref-type="fig">Fig. 5A</xref>); this observation has important implications for cell proliferation and differentiation, which are regulated by RUNX2. The FGF/FGFR2 signaling pathway is critical for proliferation in skeletogenesis (<xref rid="ref43" ref-type="bibr">43</xref>). To determine the effects of juglone on osteoblast proliferation and differentiation, we performed a proliferation assay and assessed the mRNA levels of marker genes in WT and <italic>Fgfr2<sup>S252W/+</sup></italic> primary mouse calvarial cells. Cell growth (<xref rid="f5" ref-type="fig">Fig. 5B</xref>) and expression of proliferation marker genes such as <italic>CyclinD1</italic>, <italic>Cdk2</italic>, <italic>Cdk4</italic> and <italic>PCNA</italic> were higher in <italic>Fgfr2<sup>S252W/+</sup></italic> calvarial cells than in WT cells (<xref rid="f5" ref-type="fig">Fig. 5C</xref>&#x02013;<xref rid="f5" ref-type="fig">F</xref>). Administration of juglone decreased cell growth (<xref rid="f5" ref-type="fig">Fig. 5B</xref>), as well as the expression of proliferation marker genes (<xref rid="f5" ref-type="fig">Fig. 5C</xref>&#x02013;<xref rid="f5" ref-type="fig">F</xref>), in a dose-dependent manner. Transcript levels of bone marker genes followed a similar pattern (<xref rid="f5" ref-type="fig">Fig. 5G</xref> and <xref rid="f5" ref-type="fig">H</xref>). Suppression of PIN1 by juglone almost completely abrogated the higher expression of specific genes induced by <italic>Fgfr2<sup>S252W</sup></italic> mutation. During osteoblast maturation, <italic>Fgfr2<sup>S252W/+</sup></italic> calvarial cells exhibited enhanced production of mineralized bone matrix compared with WT cells, as detected by alizarin red staining (<xref rid="f5" ref-type="fig">Fig. 5I</xref>); juglone rescued this phenotype in a concentration-dependent manner (<xref rid="f5" ref-type="fig">Fig. 5I</xref>). Together, these data suggest that juglone reduces the transcriptional activity of RUNX2 and abrogates the effects of <italic>Fgfr2</italic> mutation, namely, excessive osteoblast differentiation resulting in CS.</p><fig id="f5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Effects of juglone treatment on osteoblast proliferation and differentiation. (<bold>A</bold>) Relative RUNX2 transacting activity was assessed using a 6XOSE2 luciferase reporter construct. Following transfection with the 6XOSE2 reporter gene, cells were treated with juglone at various concentrations for 24&#x000a0;h. Luciferase assays were performed on both WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mouse calvarial cells. (<bold>B</bold>) Proliferation of WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mouse calvarial cells following treatment with various doses of juglone for 1, 3 and 7&#x000a0;days. Cell proliferation was assessed by water-soluble tetrazolium assay. (<bold>C</bold>&#x02013;<bold>F</bold>) Relative expression of proliferation-related genes in WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mouse calvarial cells, as determined by qPCR. (<bold>G</bold>&#x02013;<bold>H</bold>) Relative expression of osteoblast differentiation markers in both genotypes of primary mouse calvarial cells, as determined by qPCR. Cells were treated with vehicle or 5&#x000a0;&#x003bc;<sc>m</sc> juglone for 24&#x000a0;h and were more cultured for 2&#x000a0;days in osteogenic media. Expression of each marker gene was normalized against that of <italic>Gapdh</italic> in the same sample. (<bold>I</bold>) Late-stage primary osteoblast differentiation was confirmed by Alizarin Red S staining. Both genotypes of primary calvarial cells were cultured for 3&#x000a0;weeks in osteogenic media after 48&#x000a0;h culture with the indicated concentrations of juglone (<italic>n</italic>&#x000a0;=&#x000a0;3 in each group; <sup>*</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; <sup>**</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.005; <sup>***</sup><italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p></caption><graphic xlink:href="ddy252f5"/></fig></sec></sec><sec id="sec8"><title>Discussion</title><p>The majority of severe CS cases are due to <italic>de novo</italic> mutations and are therefore usually unanticipated (<xref rid="ref1" ref-type="bibr">1</xref>). Currently, the only way to treat CS patients is surgical intervention, involving creation of an expanded but rigid skull vault to accommodate further increases in brain growth, with some additional remodeling of the inner surface of the calvaria (<xref rid="ref1" ref-type="bibr">1</xref>). However, recent developments in prenatal diagnostic testing for mutations in amniotic fluid, especially <italic>FGFR2</italic> mutations, raise the possibility of early diagnosis (<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref45" ref-type="bibr">45</xref>). Detection of CS during pregnancy could allow premature closure of the cranial suture to be prevented by inhibiting excessive growth at the developmental stage of the fetus using a drug. This approach is promising in that it not only alleviates the burden of surgery in infants but could also prevent mental retardation caused by delayed surgery or surgery sequela arising during brain growth.</p><p>In this study, we generated <italic>Pin1;Fgfr2</italic> compound mutant mice and investigated the effects of juglone, an inhibitor of PIN1, on the recovery of CS phenotypes such as early suture closure in <italic>Fgfr2<sup>S252W/+</sup></italic> mice (<xref rid="f1" ref-type="fig">Figs. 1</xref> and <xref rid="f2" ref-type="fig">2</xref> and <xref ref-type="supplementary-material" rid="sup1">Supplementary Material Figs. S1</xref> and <xref ref-type="supplementary-material" rid="sup1">S3</xref>). Many studies have been conducted to elucidate the factors that cause CS or identify therapeutic targets for CS. Wang <italic>et al.</italic> demonstrated the importance of the p38 mitogen-activated protein kinase (MAPK) pathway in AS, which is caused by mutations in FGFR2 (<xref rid="ref24" ref-type="bibr">24</xref>). Tanimoto <italic>et al.</italic> showed that the CS phenotype of mice homozygous for the <italic>Gli3</italic> deletion can be rescued through the removal of one allele of <italic>Runx2</italic> (<xref rid="ref46" ref-type="bibr">46</xref>). In addition to this genetic approach, Shukla <italic>et al.</italic> reported that U0126, which suppresses ERK/MAPK signaling, prevents premature cranial suture closure in <italic>Fgfr2<sup>S252W/+</sup></italic> mice (<xref rid="ref22" ref-type="bibr">22</xref>). Usually, the ERK/MAPK enzyme action products are shared with a substrate for the PIN1 enzyme, because PIN1 binds only to the pSer/Thr-Pro motif (<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref47" ref-type="bibr">47</xref>). Therefore, inhibition of PIN1 disrupts signaling downstream of the ERK/MAP kinase pathway, and it is possible that it would result in fewer non-specific effects than the inhibition of ERK-MAP kinase. In addition, in our genetic approach, we demonstrated that targeting the <italic>Pin1</italic> gene in <italic>Fgfr2<sup>S252W/+</sup></italic> mice leads to AS phenotype recovery (<xref rid="f1" ref-type="fig">Fig. 1</xref>), supporting the conclusion drawn from our pharmacological approach that juglone-mediated rescue is indeed due to inhibition of PIN1 (<xref rid="f2" ref-type="fig">Fig. 2</xref>). Accordingly, we propose that PIN1-targeted therapy would be valuable for treatment of CS.</p><p>This approach could also be applied to alleviating other phenotypes associated with FGFR-related CS. These phenotypes differ slightly different depending on the type of <italic>FGFR</italic> mutation (<xref rid="ref8" ref-type="bibr">8</xref>,<xref rid="ref48" ref-type="bibr">48</xref>). The <italic>FGFR S252W</italic> mutation, as in AS, causes premature fusion of the coronal suture with syndactyly of the hands or feet, mid-face hypoplasia and dwarfism (<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref49" ref-type="bibr">49</xref>,<xref rid="ref50" ref-type="bibr">50</xref>). As described previously (<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref24" ref-type="bibr">24</xref>,<xref rid="ref50" ref-type="bibr">50</xref>), we also observed abnormalities in endochondral bone formation, as evidenced by shorter body length (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Figs. S1</xref> and <xref ref-type="supplementary-material" rid="sup1">S3</xref>) and shortening of the skull (<xref rid="f1" ref-type="fig">Figs. 1</xref> and <xref rid="f2" ref-type="fig">2</xref>) in <italic>Fgfr2<sup>S252W</sup></italic> mutant mice. In addition to fusion of the calvarial sutures, mid-face growth is also an important factor affecting skull length (<xref rid="ref51" ref-type="bibr">51</xref>), and these phenotypes are caused by increased endochondral ossification due to gain-of-function mutation in <italic>FGFR</italic>s (<xref rid="ref52" ref-type="bibr">52</xref>). We found that inactivation of PIN1 by genetic manipulation or drug treatment restored body size (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Figs. S1</xref> and <xref ref-type="supplementary-material" rid="sup1">S3</xref>) and skull length (<xref rid="f1" ref-type="fig">Figs. 1</xref> and <xref rid="f2" ref-type="fig">2</xref>). These effects of PIN1 targeting might also be applied to endochondral ossification processes. Furthermore, these bone phenotypes are similar to those in patients with AS and achondroplasia, the most common genetic dwarfism in humans, which is caused by mutation in <italic>FGFR3</italic> (<xref rid="ref53" ref-type="bibr">53</xref>). CS can be classified as syndromic based on <italic>FGFR</italic> gene mutations and associated phenotypes. Although we used only the <italic>Fgfr2</italic><sup><italic>S252W</italic>/+</sup> CS mouse model in this study, CS is also caused by mutations in other <italic>FGFR</italic>s, including <italic>FGFR1</italic>, <italic>FGFR2</italic> or <italic>FGFR3</italic> (<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref8" ref-type="bibr">8</xref>). Some of these mutations, such as <italic>FGFR2<sup>S252W</sup></italic>, increase the affinity of the receptor for ligand, whereas others cause excessive signaling via ligand-independent receptor activation (<xref rid="ref8" ref-type="bibr">8</xref>,<xref rid="ref48" ref-type="bibr">48</xref>). However, we found that early fused cranial sutures are rescued by targeting PIN1, which suppresses hyperactivated downstream signaling of the FGF/FGFR signaling, a common feature of <italic>FGFR</italic> mutants. Therefore, we propose that this approach might also be applicable for the therapy of other CS syndromes, such as those caused by gain-of-function mutations in other <italic>FGFR</italic>s.</p><p>Recovery rates from nasal&#x02013;frontal suture fusion by genetic deletion or inhibition of PIN1 were different from observed recovery rates from coronal suture fusion (<xref rid="TB1" ref-type="table">Tables 1</xref> and <xref rid="TB2" ref-type="table">2</xref>). We proposed two reasons for these. First, it seems that suture fusion patterns are a suture-specific consequence of a complex combination of biogenesis or signaling in the sutures and variation in individual timing specific to each suture (<xref rid="ref54" ref-type="bibr">54</xref>). Therefore, the degree or timing of the FGFR2 signaling effect differs depending on the type of suture (<xref rid="ref55" ref-type="bibr">55&#x02013;57</xref>). Second, areas of the skull derived from the lineage in the coronal suture are developmentally distinct from areas in nasal&#x02013;frontal suture, because of the mixed developmental origin of the mammalian skull vault (<xref rid="ref54" ref-type="bibr">54</xref>,<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref59" ref-type="bibr">59</xref>): the frontal and sagittal suture are neural crest derived, whereas the parietal bone and coronal suture are of mesodermal origin (<xref rid="ref54" ref-type="bibr">54</xref>). The main symptom of CS caused by the <italic>Fgfr2<sup>S252W</sup></italic> mutation is the coronal suture early fusion, so our study has focused on the effect of recovery of coronal suture fusion.</p><p>Juglone is one of the best-known PIN1 inhibitors, and its IC50 values have been reported to vary with cell type (<xref rid="ref60" ref-type="bibr">60&#x02013;62</xref>). In primary osteoblasts, we found that the IC50 value was 13.55&#x000a0;&#x003bc;<sc>m</sc> (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S4</xref>). In addition, juglone passes the placenta barrier, as demonstrated by the observation that high concentrations of juglone could induce abortion (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S2</xref>). Juglone undergoes biotransformation in the liver to yield various metabolites, which are detected primarily in urine (<xref rid="ref63" ref-type="bibr">63</xref>), indicating that the compound has access to liver cells (<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref64" ref-type="bibr">64</xref>) These observations imply that juglone has the potential to regulate liver function and that it could also be used for medicinal purposes in other parts of the body (<xref rid="ref18" ref-type="bibr">18</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref64" ref-type="bibr">64</xref>). We established the appropriate concentration of juglone through toxicity testing in pregnant mice and determined a dose that did not affect the number of littermates or overall skull phenotypes (<xref ref-type="supplementary-material" rid="sup1">Supplementary Material Fig. S2</xref>). We confirmed that development of the abnormal phenotype of <italic>Fgfr2<sup>S252W/+</sup></italic> mice (small, shortened skull and premature fusion of the coronal suture) could be prevented by juglone treatment (<xref rid="f2" ref-type="fig">Fig. 2</xref>). Also, although many previous studies have reported that the survival rate of AS is low (<xref rid="ref50" ref-type="bibr">50</xref>,<xref rid="ref65" ref-type="bibr">65&#x02013;67</xref>), optimized concentrations of juglone increased the number of littermates in comparison with the control group (average control litter: 5.25 pups; average litter of juglone-injected mother: 7.11 pups). This observation suggests that juglone improves the survival of newborn mice with the <italic>Fgfr2<sup>S252W/+</sup></italic> mutation.</p><p>Together, these genetic and pharmacological approaches using juglone indicate that PIN1 is the target for juglone-mediated attenuation of hyperactivated FGF/FGFR signaling in <italic>Fgfr2<sup>S252W/+</sup></italic> mice. However, pure juglone is used only for research purposes and is categorized as an &#x02018;Unapproved Herb&#x02019; in the German Commission E monograph owing to its probably mutagenic and carcinogenic properties (<xref rid="ref64" ref-type="bibr">64</xref>). In addition, it has been designated as a potentially toxic natural product by the National Toxicology Program in the USA (<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref64" ref-type="bibr">64</xref>). Therefore, for clinical use, it would be important to develop PIN1 inhibitors that are both effective and safe.</p><p>It is widely accepted that PIN1 is a molecular switch that determines the fate of numerous osteogenic transcription factors, especially those related to stabilization of substrate proteins (<xref rid="ref13" ref-type="bibr">13&#x02013;15</xref>,<xref rid="ref17" ref-type="bibr">17</xref>,<xref rid="ref68" ref-type="bibr">68</xref>). In addition, direct delivery of PIN1 protein into mesenchymal cells stimulates their osteogenic differentiation (<xref rid="ref69" ref-type="bibr">69</xref>). We previously suggested that FGF2 induces PTMs of RUNX2. In particular, we showed that RUNX2 is acetylated by p300 (<xref rid="ref70" ref-type="bibr">70</xref>) and that FGF2-induced phosphorylation (<xref rid="ref12" ref-type="bibr">12</xref>,<xref rid="ref71" ref-type="bibr">71</xref>) and subsequent acetylation (<xref rid="ref72" ref-type="bibr">72</xref>) of RUNX2 stimulates its <italic>in vitro</italic> transactivation activity by stabilizing the protein. Also, we reported that prolyl isomerization of RUNX2 alters the conformation to an acetylation-friendly structure, resulting in stabilization and activation RUNX2 (<xref rid="ref14" ref-type="bibr">14</xref>). In this study, we found that <italic>Fgfr2<sup>S252W</sup></italic> mutation increased the RUNX2 level by promoting these PTMs, which in turn increased the nuclear RUNX2 level in <italic>Fgfr2<sup>S252W/+</sup></italic> primary calvarial cells or tissues (<xref rid="f4" ref-type="fig">Fig. 4</xref>). This increase in RUNX2 level, in addition to elevation of general FGFR signaling, resulted in excessive osteoblast proliferation and differentiation (<xref rid="f5" ref-type="fig">Fig. 5</xref>), which may be the molecular mechanism underlying premature closure of the coronal sutures in CS. Moreover, we showed that the PIN1 inhibitor juglone decreased excessive RUNX2 stabilization by inhibiting its isomerization and consequent acetylation (<xref rid="f4" ref-type="fig">Figs. 4</xref> and <xref rid="f5" ref-type="fig">5</xref>), confirming the importance of PIN1 in the RUNX2 PTM process <italic>in vivo</italic>. However, although we showed that premature coronal suture fusion rescued by controlling PIN1 was only due to decrease of RUNX2 levels, many previous studies using AS mouse models reported that phosphorylation levels of ERK1/2, AKT and p38 are elevated in the calvaria by gain-of-function mutations of FGFR2 such as S252W and P253R (<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref24" ref-type="bibr">24</xref>,<xref rid="ref73" ref-type="bibr">73</xref>,<xref rid="ref74" ref-type="bibr">74</xref>). In addition, inhibition of ERK, an important mediator of FGF signaling, restores the phenotype of AS mouse (<xref rid="ref22" ref-type="bibr">22</xref>). In a previous study, we showed that PIN1 is crucial for regulation of the FGF/FGFR signaling pathway (<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref68" ref-type="bibr">68</xref>) and that FGF target genes are affected by juglone (<xref rid="f3" ref-type="fig">Fig. 3</xref>). Therefore, we suspect that restoration of CS phenotypes via alteration of RUNX2 PTMs represents only one of many potential mediators downstream of the FGF signaling pathway.</p><p>In summary, our results indicate that PIN1 is a new therapeutic target for CS. Rescue of CS by juglone was associated with alterations in PIN1 activity and RUNX2 stability (<xref rid="f6" ref-type="fig">Fig. 6</xref>). Administration of the PIN1 inhibitor juglone during pregnancy significantly suppressed CS phenotypes, especially premature fusion of the coronal suture, in an <italic>Fgfr2<sup>S252W</sup></italic> mutant mouse model. These data clearly establish the regulatory role of PIN1 in abnormalities associated with FGF/FGFR2 hyperactivation and highlight the feasibility of developing specific targeted prevention and therapeutic strategies for CS.</p><fig id="f6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Mechanisms underlying restoration of the normal phenotype by juglone in calvaria with gain-of-function mutations in <italic>FGFR2</italic>. Juglone treatment lowers abnormally elevated RUNX2 levels in <italic>Fgfr2<sup>S252W/+</sup></italic> mice by inhibiting RUNX2 isomerization, thereby restoring proper downstream transcriptional activity (<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref83" ref-type="bibr">83</xref>). The <italic>S252W</italic> mutation of <italic>FGFR2</italic> increases ligand affinity and alters ligand specificity, resulting in hyperactive FGF signaling. In this genetic background, RUNX2, one of the targets of FGF signaling, undergoes excessive PTM, such as isomerization and acetylation. Repression of RUNX2 isomerization by juglone, a PIN1 inhibitor, decreases the RUNX2 level and normalizes the expression of RUNX2 target genes, thereby rescuing the abnormal calvaria phenotypes of <italic>Fgfr2<sup>S252W/+</sup></italic> mice.</p></caption><graphic xlink:href="ddy252f6"/></fig></sec><sec id="sec9"><title>Materials and Methods</title><sec id="sec10"><title>Animal experiments</title><p>
<italic>Fgfr2<sup>S252W/+</sup></italic> and <italic>Pin1</italic>-deficient mice (<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref75" ref-type="bibr">75</xref>) were maintained under specific pathogen-free conditions. The loxP-neo-loxP cassette, a blocker sequence, can be deleted to activate the <italic>Fgfr2<sup>S252W</sup></italic> allele upon crossing with mice carrying a ubiquitous <italic>Cre</italic> transgene (<italic>EIIA-Cre</italic>, the Jackson Laboratory, Bar Harbor, Maine, USA) (<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref76" ref-type="bibr">76</xref>). Mice carrying the <italic>Fgfr2<sup>S252W</sup></italic> and <italic>EIIA-Cre</italic> alleles were mated, and <italic>Pin1;Fgfr2</italic> compound mutant mice were generated by mating <italic>Pin1<sup>+/&#x02212;</sup>Fgfr2<sup>Neo-S252W/+</sup></italic> mice with <italic>Pin1<sup>+/&#x02212;</sup>EIIa-Cre/+</italic> mice. The genetic background of <italic>Fgfr2<sup>Neo-S252W/+</sup></italic> mice is mouse strain (FVB) (<xref rid="ref22" ref-type="bibr">22</xref>), and the <italic>EIIa-Cre</italic> transgene (B6.FVB-TgN(EIIa-cre)C5379Lm, No. 003724) was from the Jackson Laboratory. The genetic background of the <italic>Pin1<sup>+/&#x02212;</sup></italic> mice is C57BL/6 (<xref rid="ref34" ref-type="bibr">34</xref>). Pregnant mice were injected intraperitoneally with juglone (Calbiochem, Darmstadt, Germany). Skeletal staining and micro-CT analysis were performed as described previously (<xref rid="ref77" ref-type="bibr">77</xref>). The numbers of animals in experimental groups are indicated in the figure legends. Animals were housed in cages following Institutional Animal Care and Use Committee (IACUC) policies. All animal studies were reviewed and approved by the Special Committee on Animal Welfare, Seoul National University, Seoul, Republic of Korea.</p></sec><sec id="sec11"><title>Cell culture, cell proliferation assay and luciferase reporter assay</title><p>WT and <italic>Fgfr2<sup>S252W/+</sup></italic> mice calvarial cells were isolated from newborn mice. Primary calvarial cells and pre-osteoblast MC3T3-E1 cells were cultured in &#x003b1;-minimum essential medium (&#x003b1;-MEM) with 10% fetal bovine serum containing 1% penicillin/streptomycin. For osteogenic differentiation, the medium was supplemented with 5&#x000a0;m<sc>m</sc> &#x003b2;-glycerophosphate and 50&#x000a0;&#x003bc;g/ml ascorbic acid. Cell proliferation was assayed as previously described (<xref rid="ref77" ref-type="bibr">77</xref>), and luciferase activity was detected using the Luciferase Assay Kit (Promega, Madison, WI, USA) (<xref rid="ref17" ref-type="bibr">17</xref>).</p></sec><sec id="sec12"><title>Histology analysis</title><p>For hematoxylin and eosin (H&#x00026;E) staining and IHC of tissue sections, newborn mice were fixed in 4% paraformaldehyde for 24&#x000a0;h, dehydrated and embedded in paraffin using standard procedures. Serial paraffin sections (5&#x000a0;&#x003bc;m thickness) were subjected to H&#x00026;E staining as described previously (<xref rid="ref13" ref-type="bibr">13</xref>) or IHC using the EnVision&#x02122; G|2 Doublestain System (Dako, Glostrup, Denmark) (<xref rid="ref77" ref-type="bibr">77</xref>). Stained tissues were imaged on a conventional microscope equipped with a DP72 digital camera (Olympus, Tokyo, Japan). Antibodies used for these experiments are listed in <xref ref-type="supplementary-material" rid="sup1">Supplementary Material Table S1</xref>.</p></sec><sec id="sec13"><title>Antibodies and reagents</title><p>Antibodies and reagents are described in detail in <xref ref-type="supplementary-material" rid="sup1">Supplementary Material Tables S1</xref> and <xref ref-type="supplementary-material" rid="sup1">S2</xref>.</p></sec><sec id="sec14"><title>Micro-CT analysis</title><p>Newborn mice were sacrificed and fixed with 4% paraformaldehyde overnight at 4&#x000b0;C. Micro-CT was performed on an inspeXio SMX-100CT system, and data were analyzed using the TriBON software (RATOC, Tokyo, Japan). The use of these methods for bone analyses was described previously (<xref rid="ref78" ref-type="bibr">78&#x02013;80</xref>).</p></sec><sec id="sec15"><title>Extraction of total RNAs, RT-PCR and quantitative real-time PCR</title><p>Total RNA extraction from cultured cells, RT-PCR and real-time PCR (qPCR) were performed as described previously (<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref80" ref-type="bibr">80</xref>). The primer sets used for qPCR are listed in <xref ref-type="supplementary-material" rid="sup1">Supplementary Material Table S3</xref> and in (<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref77" ref-type="bibr">77</xref>,<xref rid="ref80" ref-type="bibr">80</xref>). mRNA expression was determined by qPCR, and the results were normalized to the <italic>Gapdh</italic> expression level.</p></sec><sec id="sec16"><title>DNA construction and transfection</title><p>Construction of <italic>Fgfr2<sup>WT</sup></italic> and <italic>Fgfr2<sup>S252W</sup></italic> mutant expression vectors was described previously (<xref rid="ref81" ref-type="bibr">81</xref>). Transactivation activity of RUNX2 was evaluated using the 6XOSE2-Luc reporter vector (<xref rid="ref12" ref-type="bibr">12</xref>). The Neon transfection system (Invitrogen, San Diego, CA, USA) was used for DNA transfection of primary mouse calvarial cells or MC3T3-E1 cells.</p></sec><sec id="sec17"><title>Nuclear&#x02013;cytoplasmic fractionation and immunoassays</title><p>Nuclear&#x02013;cytoplasmic fractionation was conducted as previously described (<xref rid="ref17" ref-type="bibr">17</xref>). Detection of cellular proteins by IP and immunoblot assays and detection of RUNX2 by immunofluorescence were carried out as described previously (<xref rid="ref14" ref-type="bibr">14</xref>).</p></sec><sec id="sec18"><title>Alizarin Red S staining</title><p>Detection of mineralized bone matrix production was performed as described previously (<xref rid="ref82" ref-type="bibr">82</xref>).</p></sec><sec id="sec19"><title>Statistics</title><p>All quantitative data are presented as means&#x000a0;&#x000b1;&#x000a0;SD (<italic>in vitro</italic> data) or means&#x000a0;&#x000b1;&#x000a0;SEM (<italic>in vivo</italic> data). Each experiment was performed at least three times, and results from representative individual experiments are shown in the figures. Statistical analysis was performed by either unpaired two-tailed Student&#x02019;s <italic>t</italic>-test or one-way analysis of variance followed by Bonferroni&#x02019;s test using the Prism 5.0 software (GraphPad Software, San Diego, CA, USA). <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05 was considered significant.</p></sec><sec id="sec20"><title>Study approval</title><p>The Seoul National University IACUCs approved the animal study (Approval No. SNU-160121-1).</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="sup1"><label>Supplementary Data</label><media xlink:href="ddy252_supp.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><title>Acknowledgements</title><p>The authors thank C.X. Deng (University of Macau, China) for providing the <italic>Fgfr2</italic><sup>S252W</sup> knock-in mouse and S.C. Bae (Chungbuk National University, Cheongju, Korea) for providing valuable advice on pharmacokinetics.</p><p>
<italic>Conflict of Interest statement.</italic> None declared.</p></ack><sec id="sec21"><title>Funding</title><p>General Researcher Program of the National Research Foundation of Korea (NRF-2014R1A2A2A01004865, NRF-2017R1A2B3011778).</p></sec><ref-list><title>References</title><ref id="ref1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>D.</given-names></name> and <name name-style="western"><surname>Wilkie</surname><given-names>A.O.</given-names></name></person-group> (<year>2011</year>) <article-title>Craniosynostosis</article-title>. <source><italic toggle="yes">Eur. J. Hum. Genet.</italic></source>, <volume>19</volume>, <fpage>369</fpage>&#x02013;<lpage>376</lpage>.<pub-id pub-id-type="pmid">21248745</pub-id></mixed-citation></ref><ref id="ref2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Clendenning</surname><given-names>D.E.</given-names></name> and <name name-style="western"><surname>Mortlock</surname><given-names>D.P.</given-names></name></person-group> (<year>2012</year>) <article-title>The BMP ligand Gdf6 prevents differentiation of coronal suture mesenchyme in early cranial development</article-title>. <source><italic toggle="yes">PloS One</italic></source>, <volume>7</volume>, <fpage>e36789</fpage>.<pub-id pub-id-type="pmid">22693558</pub-id></mixed-citation></ref><ref id="ref3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>S.W.</given-names></name>, <name name-style="western"><surname>Sim</surname><given-names>K.B.</given-names></name> and <name name-style="western"><surname>Kim</surname><given-names>S.D.</given-names></name></person-group> (<year>2016</year>) <article-title>Development and growth of the normal cranial vault: an embryologic review</article-title>. <source><italic toggle="yes">J. Korean Neurosurg. Soc.</italic></source>, <volume>59</volume>, <fpage>192</fpage>&#x02013;<lpage>196</lpage>.<pub-id pub-id-type="pmid">27226848</pub-id></mixed-citation></ref><ref id="ref4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Derderian</surname><given-names>C.</given-names></name> and <name name-style="western"><surname>Seaward</surname><given-names>J.</given-names></name></person-group> (<year>2012</year>) <article-title>Syndromic craniosynostosis</article-title>. <source><italic toggle="yes">Semin. Plast. Surg.</italic></source>, <volume>26</volume>, <fpage>64</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">23633933</pub-id></mixed-citation></ref><ref id="ref5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bagheri-Fam</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Ono</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Katsura</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Rossello</surname><given-names>F.J.</given-names></name>, <name name-style="western"><surname>Koopman</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Scherer</surname><given-names>G.</given-names></name><etal>et al.</etal></person-group> (<year>2015</year>) <article-title>FGFR2 mutation in 46,XY sex reversal with craniosynostosis</article-title>. <source><italic toggle="yes">Hum. Mol. Genet.</italic></source>, <volume>24</volume>, <fpage>6699</fpage>&#x02013;<lpage>6710</lpage>.<pub-id pub-id-type="pmid">26362256</pub-id></mixed-citation></ref><ref id="ref6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Weng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Q.</given-names></name>, and <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>) <article-title>Dynamic morphological changes in the skulls of mice mimicking human Apert syndrome resulting from gain-of-function mutation of FGFR2 (P253R)</article-title>. <source><italic toggle="yes">J. Anat.</italic></source>, <volume>217</volume>, <fpage>97</fpage>&#x02013;<lpage>105</lpage>.<pub-id pub-id-type="pmid">20557404</pub-id></mixed-citation></ref><ref id="ref7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Koca</surname><given-names>T.T.</given-names></name></person-group> (<year>2016</year>) <article-title>Apert syndrome: a case report and review of the literature</article-title>. <source><italic toggle="yes">North. Clin. Istanb.</italic></source>, <volume>3</volume>, <fpage>135</fpage>&#x02013;<lpage>139</lpage>.<pub-id pub-id-type="pmid">28058401</pub-id></mixed-citation></ref><ref id="ref8"><label>8</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Robin</surname><given-names>N.H.</given-names></name>, <name name-style="western"><surname>Falk</surname><given-names>M.J.</given-names></name> and <name name-style="western"><surname>Haldeman-Englert</surname><given-names>C.R.</given-names></name></person-group> (<year>1993</year>) <person-group person-group-type="author"><name name-style="western"><surname>Pagon</surname><given-names>R.A.</given-names></name>, <name name-style="western"><surname>Adam</surname><given-names>M.P.</given-names></name>, <name name-style="western"><surname>Ardinger</surname><given-names>H.H.</given-names></name>, <name name-style="western"><surname>Wallace</surname><given-names>S.E.</given-names></name>, <name name-style="western"><surname>Amemiya</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Bean</surname><given-names>L.J.H.</given-names></name>, <name name-style="western"><surname>Bird</surname><given-names>T.D.</given-names></name>, <name name-style="western"><surname>Ledbetter</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Mefford</surname><given-names>H.C.</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>R.J.H.</given-names></name> and <name name-style="western"><surname>Stephens</surname><given-names>K.</given-names></name></person-group> (eds.), In <source><italic toggle="yes">GeneReviews(R)</italic></source>, <publisher-loc>Seattle (WA)</publisher-loc>, <comment>in press</comment>.</mixed-citation></ref><ref id="ref9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ibrahimi</surname><given-names>O.A.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Eliseenkova</surname><given-names>A.V.</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Linhardt</surname><given-names>R.J.</given-names></name> and <name name-style="western"><surname>Mohammadi</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>) <article-title>Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities</article-title>. <source><italic toggle="yes">Hum. Mol. Genet.</italic></source>, <volume>13</volume>, <fpage>2313</fpage>&#x02013;<lpage>2324</lpage>.<pub-id pub-id-type="pmid">15282208</pub-id></mixed-citation></ref><ref id="ref10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Burns</surname><given-names>H.D.</given-names></name>, <name name-style="western"><surname>Enriquez-Harris</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Wilkie</surname><given-names>A.O.</given-names></name> and <name name-style="western"><surname>Heath</surname><given-names>J.K.</given-names></name></person-group> (<year>1998</year>) <article-title>Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand</article-title>. <source><italic toggle="yes">Hum. Mol. Genet.</italic></source>, <volume>7</volume>, <fpage>1475</fpage>&#x02013;<lpage>1483</lpage>.<pub-id pub-id-type="pmid">9700203</pub-id></mixed-citation></ref><ref id="ref11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nakamura</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kosugi</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>D.Y.</given-names></name>, <name name-style="western"><surname>Hafner</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sinclair</surname><given-names>D.A.</given-names></name>, <name name-style="western"><surname>Ryo</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Lu</surname><given-names>K.P.</given-names></name></person-group> (<year>2012</year>) <article-title>Prolyl isomerase Pin1 regulates neuronal differentiation via beta-catenin</article-title>. <source><italic toggle="yes">Mol. Cell. Biol.</italic></source>, <volume>32</volume>, <fpage>2966</fpage>&#x02013;<lpage>2978</lpage>.<pub-id pub-id-type="pmid">22645310</pub-id></mixed-citation></ref><ref id="ref12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2003</year>) <article-title>The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>278</volume>, <fpage>319</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">12403780</pub-id></mixed-citation></ref><ref id="ref13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Uchida</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Komori</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Wijnen</surname><given-names>A.</given-names><prefix>van</prefix></name>, <name name-style="western"><surname>Stein</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Lian</surname><given-names>J.B.</given-names></name><etal>et al.</etal></person-group> (<year>2013</year>) <article-title>Pin1-mediated Runx2 modification is critical for skeletal development</article-title>. <source><italic toggle="yes">J. Cell. Physiol.</italic></source>, <volume>228</volume>, <fpage>2377</fpage>-<lpage>2385</lpage>.<pub-id pub-id-type="pmid">23702614</pub-id></mixed-citation></ref><ref id="ref14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>H.S.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>S.C.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2014</year>) <article-title>Prolyl isomerase Pin1-mediated conformational change and subnuclear focal accumulation of Runx2 are crucial for fibroblast growth factor 2 (FGF2)-induced osteoblast differentiation</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>289</volume>, <fpage>8828</fpage>&#x02013;<lpage>8838</lpage>.<pub-id pub-id-type="pmid">24509851</pub-id></mixed-citation></ref><ref id="ref15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Ryu</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>H.R.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2015</year>) <article-title>Pin1 plays a critical role as a molecular switch in canonical BMP signaling</article-title>. <source><italic toggle="yes">J. Cell. Physiol.</italic></source>, <volume>230</volume>, <fpage>640</fpage>&#x02013;<lpage>647</lpage>.<pub-id pub-id-type="pmid">25187260</pub-id></mixed-citation></ref><ref id="ref16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2016</year>) <article-title>Direct delivery of recombinant Pin1 protein rescued osteoblast differentiation of Pin1 deficient cells</article-title>. <source><italic toggle="yes">J. Cell. Physiol.</italic></source>, <comment>in press</comment>.</mixed-citation></ref><ref id="ref17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Shin</surname><given-names>H.R.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>H.S.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2016</year>) <article-title>Pin1-mediated modification prolongs the nuclear retention of beta-catenin in Wnt3a-induced osteoblast differentiation</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>291</volume>, <fpage>5555</fpage>&#x02013;<lpage>5565</lpage>.<pub-id pub-id-type="pmid">26740630</pub-id></mixed-citation></ref><ref id="ref18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hennig</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Christner</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Kipping</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Schelbert</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Rucknagel</surname><given-names>K.P.</given-names></name>, <name name-style="western"><surname>Grabley</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Kullertz</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Fischer</surname><given-names>G.</given-names></name></person-group> (<year>1998</year>) <article-title>Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone</article-title>. <source><italic toggle="yes">Biochemistry</italic></source>, <volume>37</volume>, <fpage>5953</fpage>&#x02013;<lpage>5960</lpage>.<pub-id pub-id-type="pmid">9558330</pub-id></mixed-citation></ref><ref id="ref19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reese</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Vidyasagar</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Jacobson</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Acun</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Esnault</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Hullett</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Malter</surname><given-names>J.S.</given-names></name> and <name name-style="western"><surname>Djamali</surname><given-names>A.</given-names></name></person-group> (<year>2010</year>) <article-title>The Pin 1 inhibitor juglone attenuates kidney fibrogenesis via Pin 1-independent mechanisms in the unilateral ureteral occlusion model</article-title>. <source><italic toggle="yes">Fibrogenesis Tissue Repair</italic></source>, <volume>3</volume>, <issue>1</issue>.</mixed-citation></ref><ref id="ref20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>H.G.</given-names></name>, <name name-style="western"><surname>Pokharel</surname><given-names>Y.R.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Hwang</surname><given-names>Y.P.</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>E.H.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Ahn</surname><given-names>S.G.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>K.Y.</given-names></name> and <name name-style="western"><surname>Kang</surname><given-names>K.W.</given-names></name></person-group> (<year>2009</year>) <article-title>Novel role of Pin1 induction in type II collagen-mediated rheumatoid arthritis</article-title>. <source><italic toggle="yes">J. Immunol.</italic></source>, <volume>183</volume>, <fpage>6689</fpage>&#x02013;<lpage>6697</lpage>.<pub-id pub-id-type="pmid">19846884</pub-id></mixed-citation></ref><ref id="ref21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Aithal</surname><given-names>K.B.</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>B.N.</given-names></name>, <name name-style="western"><surname>Udupa</surname><given-names>N.</given-names></name> and <name name-style="western"><surname>Rao</surname><given-names>S.B.</given-names></name></person-group> (<year>2012</year>) <article-title>Tumor growth inhibitory effect of juglone and its radiation sensitizing potential: in vivo and in vitro studies</article-title>. <source><italic toggle="yes">Integr. Cancer. Ther.</italic></source>, <volume>11</volume>, <fpage>68</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">21498474</pub-id></mixed-citation></ref><ref id="ref22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Shukla</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Coumoul</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>R.H.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.S.</given-names></name> and <name name-style="western"><surname>Deng</surname><given-names>C.X.</given-names></name></person-group> (<year>2007</year>) <article-title>RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis</article-title>. <source><italic toggle="yes">Nat. Genet.</italic></source>, <volume>39</volume>, <fpage>1145</fpage>&#x02013;<lpage>1150</lpage>.<pub-id pub-id-type="pmid">17694057</pub-id></mixed-citation></ref><ref id="ref23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miura</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Perlyn</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Kinboshi</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ogihara</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Kobayashi-Miura</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Morriss-Kay</surname><given-names>G.M.</given-names></name> and <name name-style="western"><surname>Shiota</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>) <article-title>Mechanism of skull suture maintenance and interdigitation</article-title>. <source><italic toggle="yes">J. Anat.</italic></source>, <volume>215</volume>, <fpage>642</fpage>&#x02013;<lpage>655</lpage>.<pub-id pub-id-type="pmid">19811566</pub-id></mixed-citation></ref><ref id="ref24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Uhlhorn</surname><given-names>V.L.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Peter</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Martinez-Abadias</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>C.A.</given-names></name>, <name name-style="western"><surname>Percival</surname><given-names>C.J.</given-names></name>, <name name-style="western"><surname>Richtsmeier</surname><given-names>J.T.</given-names></name>, <name name-style="western"><surname>Huso</surname><given-names>D.L.</given-names></name><etal>et al.</etal></person-group> (<year>2010</year>) <article-title>Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice</article-title>. <source><italic toggle="yes">BMC Dev. Biol.</italic></source>, <volume>10</volume>, <fpage>22</fpage>.<pub-id pub-id-type="pmid">20175913</pub-id></mixed-citation></ref><ref id="ref25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Deckelbaum</surname><given-names>R.A.</given-names></name>, <name name-style="western"><surname>Majithia</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Booker</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Henderson</surname><given-names>J.E.</given-names></name> and <name name-style="western"><surname>Loomis</surname><given-names>C.A.</given-names></name></person-group> (<year>2006</year>) <article-title>The homeoprotein engrailed 1 has pleiotropic functions in calvarial intramembranous bone formation and remodeling</article-title>. <source><italic toggle="yes">Development</italic></source>, <volume>133</volume>, <fpage>63</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">16319118</pub-id></mixed-citation></ref><ref id="ref26"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Motch Perrine</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Stecko</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Neuberger</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Jabs</surname><given-names>E.W.</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>T.M.</given-names></name> and <name name-style="western"><surname>Richtsmeier</surname><given-names>J.T.</given-names></name></person-group> (<year>2017</year>) <article-title>Integration of brain and skull in prenatal mouse models of Apert and Crouzon syndromes</article-title>. <source><italic toggle="yes">Front. Hum. Neurosci.</italic></source>, <volume>11</volume>, <fpage>369</fpage>.<pub-id pub-id-type="pmid">28790902</pub-id></mixed-citation></ref><ref id="ref27"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Purushothaman</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Cox</surname><given-names>T.C.</given-names></name>, <name name-style="western"><surname>Maga</surname><given-names>A.M.</given-names></name> and <name name-style="western"><surname>Cunningham</surname><given-names>M.L.</given-names></name></person-group> (<year>2011</year>) <article-title>Facial suture synostosis of newborn Fgfr1(P250R/+) and Fgfr2(S252W/+) mouse models of Pfeiffer and Apert syndromes</article-title>. <source><italic toggle="yes">Birth Defects Res. A Clin. Mol. Teratol.</italic></source>, <volume>91</volume>, <fpage>603</fpage>&#x02013;<lpage>609</lpage>.<pub-id pub-id-type="pmid">21538817</pub-id></mixed-citation></ref><ref id="ref28"><label>28</label><mixed-citation publication-type="other">
<person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>D.P.</given-names></name></person-group> (<year>2008</year>) <chapter-title>Craniofacial sutures. Development, disease and treatment. Preface</chapter-title>
<source><italic toggle="yes">Front. Oral Biol.</italic>, <bold>12</bold> xi</source>.</mixed-citation></ref><ref id="ref29"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Maga</surname><given-names>A.M.</given-names></name>, <name name-style="western"><surname>Navarro</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Cunningham</surname><given-names>M.L.</given-names></name> and <name name-style="western"><surname>Cox</surname><given-names>T.C.</given-names></name></person-group> (<year>2015</year>) <article-title>Quantitative trait loci affecting the 3D skull shape and size in mouse and prioritization of candidate genes in-silico</article-title>. <source><italic toggle="yes">Front. Physiol.</italic></source>, <volume>6</volume>, <fpage>92</fpage>.<pub-id pub-id-type="pmid">25859222</pub-id></mixed-citation></ref><ref id="ref30"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2016</year>) <article-title>Pin1, the master orchestrator of bone cell differentiation</article-title>. <source><italic toggle="yes">J. Cell. Physiol.</italic></source>, <comment>in press</comment>.</mixed-citation></ref><ref id="ref31"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>T.G.</given-names></name>, <name name-style="western"><surname>Sweetman</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Keyse</surname><given-names>S.M.</given-names></name> and <name name-style="western"><surname>Munsterberg</surname><given-names>A.</given-names></name></person-group> (<year>2005</year>) <article-title>Feedback interactions between MKP3 and ERK MAP kinase control scleraxis expression and the specification of rib progenitors in the developing chick somite</article-title>. <source><italic toggle="yes">Development</italic></source>, <volume>132</volume>, <fpage>1305</fpage>&#x02013;<lpage>1314</lpage>.<pub-id pub-id-type="pmid">15716340</pub-id></mixed-citation></ref><ref id="ref32"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Faedo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Borello</surname><given-names>U.</given-names></name> and <name name-style="western"><surname>Rubenstein</surname><given-names>J.L.</given-names></name></person-group> (<year>2010</year>) <article-title>Repression of Fgf signaling by sprouty1-2 regulates cortical patterning in two distinct regions and times</article-title>. <source><italic toggle="yes">J. Neurosci.</italic></source>, <volume>30</volume>, <fpage>4015</fpage>&#x02013;<lpage>4023</lpage>.<pub-id pub-id-type="pmid">20237272</pub-id></mixed-citation></ref><ref id="ref33"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Fang</surname><given-names>W.</given-names></name></person-group> (<year>2015</year>) <article-title>Potential mechanisms underlying the Runx2 induced osteogenesis of bone marrow mesenchymal stem cells</article-title>. <source><italic toggle="yes">Am. J. Transl. Res.</italic></source>, <volume>7</volume>, <fpage>2527</fpage>&#x02013;<lpage>2535</lpage>.<pub-id pub-id-type="pmid">26885254</pub-id></mixed-citation></ref><ref id="ref34"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Komori</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Yagi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Nomura</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Sasaki</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Deguchi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Shimizu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Bronson</surname><given-names>R.T.</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Y.H.</given-names></name>, <name name-style="western"><surname>Inada</surname><given-names>M.</given-names></name><etal>et al.</etal></person-group> (<year>1997</year>) <article-title>Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts</article-title>. <source><italic toggle="yes">Cell</italic></source>, <volume>89</volume>, <fpage>755</fpage>&#x02013;<lpage>764</lpage>.<pub-id pub-id-type="pmid">9182763</pub-id></mixed-citation></ref><ref id="ref35"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>M.H.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>H.I.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name>, <name name-style="western"><surname>Nam</surname><given-names>S.H.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2001</year>) <article-title>Differential expression patterns of Runx2 isoforms in cranial suture morphogenesis</article-title>. <source><italic toggle="yes">J. Bone Miner. Res. </italic></source>, <volume>16</volume>, <fpage>885</fpage>&#x02013;<lpage>892</lpage>.<pub-id pub-id-type="pmid">11341333</pub-id></mixed-citation></ref><ref id="ref36"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Misteli</surname><given-names>T.</given-names></name> and <name name-style="western"><surname>Spector</surname><given-names>D.L.</given-names></name></person-group> (<year>1998</year>) <article-title>The cellular organization of gene expression</article-title>. <source><italic toggle="yes">Curr. Opin. Cell. Biol.</italic></source>, <volume>10</volume>, <fpage>323</fpage>&#x02013;<lpage>331</lpage>.<pub-id pub-id-type="pmid">9640532</pub-id></mixed-citation></ref><ref id="ref37"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Iborra</surname><given-names>F.J.</given-names></name>, <name name-style="western"><surname>Pombo</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>McManus</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>D.A.</given-names></name> and <name name-style="western"><surname>Cook</surname><given-names>P.R.</given-names></name></person-group> (<year>1996</year>) <article-title>The topology of transcription by immobilized polymerases</article-title>. <source><italic toggle="yes">Exp. Cell. Res.</italic></source>, <volume>229</volume>, <fpage>167</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">8986593</pub-id></mixed-citation></ref><ref id="ref38"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Grande</surname><given-names>M.A.</given-names></name>, <name name-style="western"><surname>Kraan</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Jong</surname><given-names>L.</given-names></name> and <name name-style="western"><surname>Driel</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>) <article-title>Nuclear distribution of transcription factors in relation to sites of transcription and RNA polymerase II</article-title>. <source><italic toggle="yes">J. Cell. Sci.</italic></source>, <volume>110</volume> ( <issue>Pt 15</issue>), <fpage>1781</fpage>-<lpage>1791</lpage>.<pub-id pub-id-type="pmid">9264465</pub-id></mixed-citation></ref><ref id="ref39"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Szentirmay</surname><given-names>M.N.</given-names></name> and <name name-style="western"><surname>Sawadogo</surname><given-names>M.</given-names></name></person-group> (<year>2000</year>) <article-title>Spatial organization of RNA polymerase II transcription in the nucleus</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>28</volume>, <fpage>2019</fpage>&#x02013;<lpage>2025</lpage>.<pub-id pub-id-type="pmid">10773068</pub-id></mixed-citation></ref><ref id="ref40"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Florencio-Silva</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Sasso</surname><given-names>G.R.</given-names></name>, <name name-style="western"><surname>Sasso-Cerri</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Simoes</surname><given-names>M.J.</given-names></name>, and <name name-style="western"><surname>Cerri</surname><given-names>P.S.</given-names></name></person-group> (<year>2015</year>) <article-title>Biology of bone tissue: structure, function, and factors that influence bone cells</article-title>. <source><italic toggle="yes">Biomed. Res. Int.</italic></source>, <volume>2015</volume>, <fpage>421746</fpage>.<pub-id pub-id-type="pmid">26247020</pub-id></mixed-citation></ref><ref id="ref41"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Galindo</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pratap</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>D.W.</given-names></name>, <name name-style="western"><surname>Hovhannisyan</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Im</surname><given-names>H.J.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name>, <name name-style="western"><surname>Lian</surname><given-names>J.B.</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>J.L.</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>G.S.</given-names></name> and <name name-style="western"><surname>Wijnen</surname><given-names>A.J.</given-names></name></person-group> (<year>2005</year>) <article-title>The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>280</volume>, <fpage>20274</fpage>-<lpage>20285</lpage>.<pub-id pub-id-type="pmid">15781466</pub-id></mixed-citation></ref><ref id="ref42"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Komori</surname><given-names>T.</given-names></name></person-group> (<year>2010</year>) <article-title>Regulation of osteoblast differentiation by Runx2</article-title>. <source><italic toggle="yes">Adv. Exp. Med. Biol.</italic></source>, <volume>658</volume>, <fpage>43</fpage>&#x02013;<lpage>49</lpage>.<pub-id pub-id-type="pmid">19950014</pub-id></mixed-citation></ref><ref id="ref43"><label>43</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>) <article-title>Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models</article-title>. <source><italic toggle="yes">Bone Res.</italic></source>, <volume>2</volume>, <fpage>14003</fpage>.<pub-id pub-id-type="pmid">26273516</pub-id></mixed-citation></ref><ref id="ref44"><label>44</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Twigg</surname><given-names>S.R.</given-names></name> and <name name-style="western"><surname>Wilkie</surname><given-names>A.O.</given-names></name></person-group> (<year>2015</year>) <article-title>A genetic-pathphysiological framework for craniosynostosis</article-title>. <source><italic toggle="yes">Am. J. Hum. Genet.</italic></source>, <volume>97</volume>, <fpage>359</fpage>&#x02013;<lpage>377</lpage>.<pub-id pub-id-type="pmid">26340332</pub-id></mixed-citation></ref><ref id="ref45"><label>45</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Phupong</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Srichomthong</surname><given-names>C.</given-names></name> and <name name-style="western"><surname>Shotelersuk</surname><given-names>V.</given-names></name></person-group> (<year>2004</year>) <article-title>Prenatal exclusion of Crouzon syndrome by mutation analysis of FGFR2</article-title>. <source><italic toggle="yes">Southeast Asian J. Trop. Med. Public Health</italic></source>, <volume>35</volume>, <fpage>977</fpage>&#x02013;<lpage>979</lpage>.<pub-id pub-id-type="pmid">15916101</pub-id></mixed-citation></ref><ref id="ref46"><label>46</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tanimoto</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Veistinen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Alakurtti</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Takatalo</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Rice</surname><given-names>D.P.</given-names></name></person-group> (<year>2012</year>) <article-title>Prevention of premature fusion of calvarial suture in GLI-Kruppel family member 3 (Gli3)-deficient mice by removing one allele of Runt-related transcription factor 2 (Runx2)</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>287</volume>, <fpage>21429</fpage>&#x02013;<lpage>21438</lpage>.<pub-id pub-id-type="pmid">22547067</pub-id></mixed-citation></ref><ref id="ref47"><label>47</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>McRackan</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Vincent</surname><given-names>T.S.</given-names></name> and <name name-style="western"><surname>Gert de Couet</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>) <italic>Drosophila</italic><article-title>Pin1 prolyl isomerase Dodo is a MAP kinase signal responder during oogenesis</article-title>. <source><italic toggle="yes">Nat Cell Biol</italic></source>, <volume>3</volume>, <fpage>538</fpage>&#x02013;<lpage>543</lpage>.<pub-id pub-id-type="pmid">11389437</pub-id></mixed-citation></ref><ref id="ref48"><label>48</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Teven</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Farina</surname><given-names>E.M.</given-names></name>, <name name-style="western"><surname>Rivas</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Reid</surname><given-names>R.R.</given-names></name></person-group> (<year>2014</year>) <article-title>Fibroblast growth factor (FGF) signaling in development and skeletal diseases</article-title>. <source><italic toggle="yes">Genes Dis.</italic></source>, <volume>1</volume>, <fpage>199</fpage>&#x02013;<lpage>213</lpage>.<pub-id pub-id-type="pmid">25679016</pub-id></mixed-citation></ref><ref id="ref49"><label>49</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Engel</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Deng</surname><given-names>C.X.</given-names></name></person-group> (<year>2003</year>) <article-title>A Ser252Trp [corrected] substitution in mouse fibroblast growth factor receptor 2 (Fgfr2) results in craniosynostosis</article-title>. <source><italic toggle="yes">Bone</italic></source>, <volume>33</volume>, <fpage>169</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">14499350</pub-id></mixed-citation></ref><ref id="ref50"><label>50</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Karim</surname><given-names>B.O.</given-names></name>, <name name-style="western"><surname>Iacovelli</surname><given-names>A.J.</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Lerner</surname><given-names>C.P.</given-names></name>, <name name-style="western"><surname>Richtsmeier</surname><given-names>J.T.</given-names></name>, <name name-style="western"><surname>Leszl</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Hill</surname><given-names>C.A.</given-names></name><etal>et al.</etal></person-group> (<year>2005</year>) <article-title>Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse</article-title>. <source><italic toggle="yes">Development</italic></source>, <volume>132</volume>, <fpage>3537</fpage>&#x02013;<lpage>3548</lpage>.<pub-id pub-id-type="pmid">15975938</pub-id></mixed-citation></ref><ref id="ref51"><label>51</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Morriss-Kay</surname><given-names>G.M.</given-names></name> and <name name-style="western"><surname>Wilkie</surname><given-names>A.O.</given-names></name></person-group> (<year>2005</year>) <article-title>Growth of the normal skull vault and its alteration in craniosynostosis: insights from human genetics and experimental studies</article-title>. <source><italic toggle="yes">J. Anat.</italic></source>, <volume>207</volume>, <fpage>637</fpage>&#x02013;<lpage>653</lpage>.<pub-id pub-id-type="pmid">16313397</pub-id></mixed-citation></ref><ref id="ref52"><label>52</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Weng</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name> and <name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>) <article-title>A Ser252Trp mutation in fibroblast growth factor receptor 2 (FGFR2) mimicking human Apert syndrome reveals an essential role for FGF signaling in the regulation of endochondral bone formation</article-title>. <source><italic toggle="yes">PLoS One</italic></source>, <volume>9</volume>, <fpage>e87311</fpage>.<pub-id pub-id-type="pmid">24489893</pub-id></mixed-citation></ref><ref id="ref53"><label>53</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>Y.C.</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>I.W.</given-names></name>, <name name-style="western"><surname>Pai</surname><given-names>Y.J.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.D.</given-names></name> and <name name-style="western"><surname>Chen</surname><given-names>Y.T.</given-names></name></person-group> (<year>2017</year>) <article-title>Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>, <volume>7</volume>, <fpage>43220</fpage>.<pub-id pub-id-type="pmid">28230213</pub-id></mixed-citation></ref><ref id="ref54"><label>54</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Heuze</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Basilico</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Jabs</surname><given-names>E.W.</given-names></name>, <name name-style="western"><surname>Holmes</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Richtsmeier</surname><given-names>J.T.</given-names></name></person-group> (<year>2014</year>) <article-title>Morphological comparison of the craniofacial phenotypes of mouse models expressing the Apert FGFR2 S252W mutation in neural crest- or mesoderm-derived tissues</article-title>. <source><italic toggle="yes">Bone</italic></source>, <volume>63</volume>, <fpage>101</fpage>&#x02013;<lpage>109</lpage>.<pub-id pub-id-type="pmid">24632501</pub-id></mixed-citation></ref><ref id="ref55"><label>55</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cowan</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Quarto</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Warren</surname><given-names>S.M.</given-names></name>, <name name-style="western"><surname>Salim</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Longaker</surname><given-names>M.T.</given-names></name></person-group> (<year>2003</year>) <article-title>Age-related changes in the biomolecular mechanisms of calvarial osteoblast biology affect fibroblast growth factor-2 signaling and osteogenesis</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>278</volume>, <fpage>32005</fpage>&#x02013;<lpage>32013</lpage>.<pub-id pub-id-type="pmid">12788918</pub-id></mixed-citation></ref><ref id="ref56"><label>56</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fakhry</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Ratisoontorn</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Vedhachalam</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Salhab</surname><given-names>I.</given-names></name>, <name name-style="western"><surname>Koyama</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Leboy</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Pacifici</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Kirschner</surname><given-names>R.E.</given-names></name> and <name name-style="western"><surname>Nah</surname><given-names>H.D.</given-names></name></person-group> (<year>2005</year>) <article-title>Effects of FGF-2/-9 in calvarial bone cell cultures: differentiation stage-dependent mitogenic effect, inverse regulation of BMP-2 and noggin, and enhancement of osteogenic potential</article-title>. <source><italic toggle="yes">Bone</italic></source>, <volume>36</volume>, <fpage>254</fpage>&#x02013;<lpage>266</lpage>.<pub-id pub-id-type="pmid">15780951</pub-id></mixed-citation></ref><ref id="ref57"><label>57</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Quarto</surname><given-names>N.</given-names></name> and <name name-style="western"><surname>Longaker</surname><given-names>M.T.</given-names></name></person-group> (<year>2006</year>) <article-title>FGF-2 inhibits osteogenesis in mouse adipose tissue-derived stromal cells and sustains their proliferative and osteogenic potential state</article-title>. <source><italic toggle="yes">Tissue Eng.</italic></source>, <volume>12</volume>, <fpage>1405</fpage>&#x02013;<lpage>1418</lpage>.<pub-id pub-id-type="pmid">16846339</pub-id></mixed-citation></ref><ref id="ref58"><label>58</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Quarto</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Behr</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>S.</given-names></name> and <name name-style="western"><surname>Longaker</surname><given-names>M.T.</given-names></name></person-group> (<year>2009</year>) <article-title>Differential FGF ligands and FGF receptors expression pattern in frontal and parietal calvarial bones</article-title>. <source><italic toggle="yes">Cells Tissues Organs</italic></source>, <volume>190</volume>, <fpage>158</fpage>&#x02013;<lpage>169</lpage>.<pub-id pub-id-type="pmid">19218784</pub-id></mixed-citation></ref><ref id="ref59"><label>59</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Iseki</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Maxson</surname><given-names>R.E.</given-names></name>, <name name-style="western"><surname>Sucov</surname><given-names>H.M.</given-names></name>, and <name name-style="western"><surname>Morriss-Kay</surname><given-names>G.M.</given-names></name></person-group> (<year>2002</year>) <article-title>Tissue origins and interactions in the mammalian skull vault</article-title>. <source><italic toggle="yes">Dev. Biol.</italic></source>, <volume>241</volume>, <fpage>106</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">11784098</pub-id></mixed-citation></ref><ref id="ref60"><label>60</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Avci</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Arikoglu</surname><given-names>H.</given-names></name> and <name name-style="western"><surname>Erkoc Kaya</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>) <article-title>Investigation of juglone effects on metastasis and angiogenesis in pancreatic cancer cells</article-title>. <source><italic toggle="yes">Gene</italic></source>, <volume>588</volume>, <fpage>74</fpage>&#x02013;<lpage>78</lpage>.<pub-id pub-id-type="pmid">27155528</pub-id></mixed-citation></ref><ref id="ref61"><label>61</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name> and <name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name></person-group> (<year>2015</year>) <article-title>Juglone inhibits proliferation and induces apoptosis of human cervical squamous cancer SiHa cells</article-title>. <source><italic toggle="yes">Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi</italic></source>, <volume>31</volume>, <fpage>186</fpage>&#x02013;<lpage>189</lpage>.<pub-id pub-id-type="pmid">25652859</pub-id></mixed-citation></ref><ref id="ref62"><label>62</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>S.H.</given-names></name>, <name name-style="western"><surname>Greenleaf</surname><given-names>A.L.</given-names></name> and <name name-style="western"><surname>Price</surname><given-names>D.H.</given-names></name></person-group> (<year>2001</year>) <article-title>Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription</article-title>. <source><italic toggle="yes">Nucleic Acids Res.</italic></source>, <volume>29</volume>, <fpage>767</fpage>&#x02013;<lpage>773</lpage>.<pub-id pub-id-type="pmid">11160900</pub-id></mixed-citation></ref><ref id="ref63"><label>63</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Saling</surname><given-names>S.C.</given-names></name>, <name name-style="western"><surname>Comar</surname><given-names>J.F.</given-names></name>, <name name-style="western"><surname>Mito</surname><given-names>M.S.</given-names></name>, <name name-style="western"><surname>Peralta</surname><given-names>R.M.</given-names></name> and <name name-style="western"><surname>Bracht</surname><given-names>A.</given-names></name></person-group> (<year>2011</year>) <article-title>Actions of juglone on energy metabolism in the rat liver</article-title>. <source><italic toggle="yes">Toxicol. Appl. Pharmacol.</italic></source>, <volume>257</volume>, <fpage>319</fpage>&#x02013;<lpage>327</lpage>.<pub-id pub-id-type="pmid">21945490</pub-id></mixed-citation></ref><ref id="ref64"><label>64</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.J.</given-names></name>, <name name-style="western"><surname>Lebetkin</surname><given-names>E.H.</given-names></name> and <name name-style="western"><surname>Burka</surname><given-names>L.T.</given-names></name></person-group> (<year>2005</year>) <article-title>Metabolism and disposition of juglone in male F344 rats</article-title>. <source><italic toggle="yes">Xenobiotica</italic></source>, <volume>35</volume>, <fpage>1019</fpage>&#x02013;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">16393859</pub-id></mixed-citation></ref><ref id="ref65"><label>65</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Hsu</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Jabs</surname><given-names>E.W.</given-names></name> and <name name-style="western"><surname>Elisseeff</surname><given-names>J.H.</given-names></name></person-group> (<year>2008</year>) <article-title>The study of abnormal bone development in the Apert syndrome Fgfr2+/S252W mouse using a 3D hydrogel culture model</article-title>. <source><italic toggle="yes">Bone</italic></source>, <volume>43</volume>, <fpage>55</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">18407821</pub-id></mixed-citation></ref><ref id="ref66"><label>66</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Theda</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Maestri</surname><given-names>N.E.</given-names></name>, <name name-style="western"><surname>Meyers</surname><given-names>G.A.</given-names></name>, <name name-style="western"><surname>Fryburg</surname><given-names>J.S.</given-names></name>, <name name-style="western"><surname>Dufresne</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Cohen</surname><given-names>M.M.</given-names><suffix>Jr.</suffix></name> and <name name-style="western"><surname>Jabs</surname><given-names>E.W.</given-names></name></person-group> (<year>1995</year>) <article-title>Analysis of phenotypic features and FGFR2 mutations in Apert syndrome</article-title>. <source><italic toggle="yes">Am. J. Hum. Genet.</italic></source>, <volume>57</volume>, <fpage>321</fpage>&#x02013;<lpage>328</lpage>.<pub-id pub-id-type="pmid">7668257</pub-id></mixed-citation></ref><ref id="ref67"><label>67</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Slaney</surname><given-names>S.F.</given-names></name>, <name name-style="western"><surname>Oldridge</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hurst</surname><given-names>J.A.</given-names></name>, <name name-style="western"><surname>Moriss-Kay</surname><given-names>G.M.</given-names></name>, <name name-style="western"><surname>Hall</surname><given-names>C.M.</given-names></name>, <name name-style="western"><surname>Poole</surname><given-names>M.D.</given-names></name> and <name name-style="western"><surname>Wilkie</surname><given-names>A.O.</given-names></name></person-group> (<year>1996</year>) <article-title>Differential effects of FGFR2 mutations on syndactyly and cleft palate in Apert syndrome</article-title>. <source><italic toggle="yes">Am. J. Hum. Genet.</italic></source>, <volume>58</volume>, <fpage>923</fpage>&#x02013;<lpage>932</lpage>.<pub-id pub-id-type="pmid">8651276</pub-id></mixed-citation></ref><ref id="ref68"><label>68</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2017</year>) <article-title>Pin1, the master orchestrator of bone cell differentiation</article-title>. <source><italic toggle="yes">J. Cell. Physiol.</italic></source>, <volume>232</volume>, <fpage>2339</fpage>&#x02013;<lpage>2347</lpage>.<pub-id pub-id-type="pmid">27225727</pub-id></mixed-citation></ref><ref id="ref69"><label>69</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2017</year>) <article-title>Direct delivery of recombinant Pin1 protein rescued osteoblast differentiation of Pin1-deficient cells</article-title>. <source><italic toggle="yes">J. Cell. Physiol.</italic></source>, <volume>232</volume>, <fpage>2798</fpage>&#x02013;<lpage>2805</lpage>.<pub-id pub-id-type="pmid">27800612</pub-id></mixed-citation></ref><ref id="ref70"><label>70</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jeon</surname><given-names>E.J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>K.Y.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>N.S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>M.H.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.N.</given-names></name>, <name name-style="western"><surname>Jin</surname><given-names>Y.H.</given-names></name>, <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Nishino</surname><given-names>N.</given-names></name><etal>et al.</etal></person-group> (<year>2006</year>) <article-title>Bone morphogenetic protein-2 stimulates Runx2 acetylation</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>281</volume>, <fpage>16502</fpage>&#x02013;<lpage>16511</lpage>.<pub-id pub-id-type="pmid">16613856</pub-id></mixed-citation></ref><ref id="ref71"><label>71</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>H.D.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>J.Y.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>J.K.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>H.I.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2004</year>) <article-title>Establishment and characterization of a stable cell line to evaluate cellular Runx2 activity</article-title>. <source><italic toggle="yes">J. Cell. Biochem.</italic></source>, <volume>91</volume>, <fpage>1239</fpage>&#x02013;<lpage>1247</lpage>.<pub-id pub-id-type="pmid">15048877</pub-id></mixed-citation></ref><ref id="ref72"><label>72</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>O.J.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2010</year>) <article-title>FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization</article-title>. <source><italic toggle="yes">J. Biol. Chem.</italic></source>, <volume>285</volume>, <fpage>3568</fpage>&#x02013;<lpage>3574</lpage>.<pub-id pub-id-type="pmid">20007706</pub-id></mixed-citation></ref><ref id="ref73"><label>73</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Qi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Xue</surname><given-names>J.</given-names></name><etal>et al.</etal></person-group> (<year>2008</year>) <article-title>A Pro253Arg mutation in fibroblast growth factor receptor 2 (Fgfr2) causes skeleton malformation mimicking human Apert syndrome by affecting both chondrogenesis and osteogenesis</article-title>. <source><italic toggle="yes">Bone</italic></source>, <volume>42</volume>, <fpage>631</fpage>&#x02013;<lpage>643</lpage>.<pub-id pub-id-type="pmid">18242159</pub-id></mixed-citation></ref><ref id="ref74"><label>74</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Rothschild</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>U.B.</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>C.X.</given-names></name>, <name name-style="western"><surname>Mansukhani</surname><given-names>A.</given-names></name> and <name name-style="western"><surname>Basilico</surname><given-names>C.</given-names></name></person-group> (<year>2009</year>) <article-title>Early onset of craniosynostosis in an Apert mouse model reveals critical features of this pathology</article-title>. <source><italic toggle="yes">Dev. Biol.</italic></source>, <volume>328</volume>, <fpage>273</fpage>&#x02013;<lpage>284</lpage>.<pub-id pub-id-type="pmid">19389359</pub-id></mixed-citation></ref><ref id="ref75"><label>75</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fujimori</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Takahashi</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Uchida</surname><given-names>C.</given-names></name> and <name name-style="western"><surname>Uchida</surname><given-names>T.</given-names></name></person-group> (<year>1999</year>) <article-title>Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest</article-title>. <source><italic toggle="yes">Biochem. Biophys. Res. Commun.</italic></source>, <volume>265</volume>, <fpage>658</fpage>&#x02013;<lpage>663</lpage>.<pub-id pub-id-type="pmid">10600477</pub-id></mixed-citation></ref><ref id="ref76"><label>76</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lakso</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Pichel</surname><given-names>J.G.</given-names></name>, <name name-style="western"><surname>Gorman</surname><given-names>J.R.</given-names></name>, <name name-style="western"><surname>Sauer</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Okamoto</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Alt</surname><given-names>F.W.</given-names></name> and <name name-style="western"><surname>Westphal</surname><given-names>H.</given-names></name></person-group> (<year>1996</year>) <article-title>Efficient in vivo manipulation of mouse genomic sequences at the zygote stage</article-title>. <source><italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic></source>, <volume>93</volume>, <fpage>5860</fpage>&#x02013;<lpage>5865</lpage>.<pub-id pub-id-type="pmid">8650183</pub-id></mixed-citation></ref><ref id="ref77"><label>77</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bae</surname><given-names>H.S.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>H.R.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>B.S.</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>J.M.</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>M.S.</given-names></name>, <name name-style="western"><surname>Cho</surname><given-names>S.A.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>K.Y.</given-names></name><etal>et al.</etal></person-group> (<year>2017</year>) <article-title>An HDAC inhibitor, Entinostat/MS-275, partially prevents delayed cranial suture closure in heterozygous Runx2 null mice</article-title>. <source><italic toggle="yes">J. Bone. Miner. Res.</italic></source>, in press.</mixed-citation></ref><ref id="ref78"><label>78</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>M.Z.</given-names></name>, <name name-style="western"><surname>Dawson</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>M.M.</given-names></name>, <name name-style="western"><surname>Gannon</surname><given-names>F.</given-names></name>, <name name-style="western"><surname>Heggeness</surname><given-names>M.</given-names></name> and <name name-style="western"><surname>Lee</surname><given-names>B.H.</given-names></name></person-group> (<year>2013</year>) <article-title>Quantitative imaging of murine osteoarthritic cartilage by phase-contrast micro-computed tomography</article-title>. <source><italic toggle="yes">Arthritis Rheum.</italic></source>, <volume>65</volume>, <fpage>388</fpage>&#x02013;<lpage>396</lpage>.<pub-id pub-id-type="pmid">23124630</pub-id></mixed-citation></ref><ref id="ref79"><label>79</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ruan</surname><given-names>M.Z.</given-names></name>, <name name-style="western"><surname>Cerullo</surname><given-names>V.</given-names></name>, <name name-style="western"><surname>Cela</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Clarke</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Lundgren-Akerlund</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Barry</surname><given-names>M.A.</given-names></name> and <name name-style="western"><surname>Lee</surname><given-names>B.H.</given-names></name></person-group> (<year>2016</year>) <article-title>Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes</article-title>. <source><italic toggle="yes">Mol. Ther. Methods Clin. Dev.</italic></source>, <volume>3</volume>, <fpage>16008</fpage>.<pub-id pub-id-type="pmid">27626040</pub-id></mixed-citation></ref><ref id="ref80"><label>80</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>Y.D.</given-names></name>, <name name-style="western"><surname>Bae</surname><given-names>H.S.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>D.S.</given-names></name>, <name name-style="western"><surname>Yoon</surname><given-names>W.J.</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>K.M.</given-names></name>, <name name-style="western"><surname>Baek</surname><given-names>J.H.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>J.C.</given-names></name>, <name name-style="western"><surname>Ku</surname><given-names>Y.</given-names></name> and <name name-style="western"><surname>Ryoo</surname><given-names>H.M.</given-names></name></person-group> (<year>2016</year>) <article-title>Epigenetic priming confers direct cell trans-differentiation from adipocyte to osteoblast in a transgene-free state</article-title>. <source><italic toggle="yes">J. Cell. Physiol.</italic></source>, <volume>231</volume>, <fpage>1484</fpage>&#x02013;<lpage>1494</lpage>.<pub-id pub-id-type="pmid">26335354</pub-id></mixed-citation></ref><ref id="ref81"><label>81</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tanimoto</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Yokozeki</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Hiura</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Nakanishi</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Matsumoto</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Marie</surname><given-names>P.J.</given-names></name> and <name name-style="western"><surname>Moriyama</surname><given-names>K.</given-names></name></person-group> (<year>2004</year>) <article-title>A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome</article-title>. <source><italic toggle="yes"> J. Biol. Chem.</italic></source>, <volume>279</volume>, <fpage>45926</fpage>&#x02013;<lpage>45934</lpage>.<pub-id pub-id-type="pmid">15310757</pub-id></mixed-citation></ref><ref id="ref82"><label>82</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Ryoo</surname><given-names>H.</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>J.</given-names></name> and <name name-style="western"><surname>Han</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>) <article-title>Osteogenic responses to zirconia with hydroxyapatite coating by aerosol deposition</article-title>. <source><italic toggle="yes">J. Dent. Res.</italic></source>, <volume>94</volume>, <fpage>491</fpage>&#x02013;<lpage>499</lpage>.<pub-id pub-id-type="pmid">25586588</pub-id></mixed-citation></ref><ref id="ref83"><label>83</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Herr</surname><given-names>A.B.</given-names></name>, <name name-style="western"><surname>Waksman</surname><given-names>G.</given-names></name> and <name name-style="western"><surname>Ornitz</surname><given-names>D.M.</given-names></name></person-group> (<year>2000</year>) <article-title>Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome</article-title>. <source><italic toggle="yes">Proc. Natl. Acad. Sci. USA</italic></source>, <volume>97</volume>, <fpage>14536</fpage>&#x02013;<lpage>14541</lpage>.<pub-id pub-id-type="pmid">11121055</pub-id></mixed-citation></ref></ref-list></back></article>